NOVEL FILARIID NEMATODE CYSTEINE PROTEASE PROTEINS, NUCLEIC ACID MOLECULES AND USES THEREOF

Abstract: The present invention provides for filariid nematode cysteine protease proteins; to filariid nematode cysteine protease nucleic acid molecules, in particular, Dirofilaria immitis L3 larval cysteine protease nucleic acid molecules and Onchocerca volvulus L3 larval cysteine protease nucleic acid molecules; to antibodies raised against such proteins, and to compounds that inhibit filariid nematode cysteine protease activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies and/or inhibitors. The present invention also includes therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitors, and the use of such compositions to protect an animal from disease caused by parasitic helminths.

Description: NOVEL FILARIID NEMATODE CYSTEINE PROTEASE PROTEINS, NUCLEIC ACID MOLECULES AND USES THEREOF FIELD OF THE INVENTION The present invention relates to novel filariid nematode protease genes, proteins encoded by such genes, antibodies raised against such proteins, and protease inhibitors produced using such proteins. Particular proteases of the present invention include cysteine proteases. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors, as well as their use to protect animals from disease caused by helminth parasites, such as by tissue-migrating helminths, including Dirofilaria and Onchocerca. BACKGROUND OF THE INVENTION Parasite infections in animals, including humans, are typically treated by chemical drugs, because there are essentially no efficacious vaccines available. One disadvantage with chemical drugs is that they must be administered often. For example, dogs susceptible to - heartwor are typically treated monthly to maintain protective drug levels. Repeated administration of drugs to treat parasite infections, however, often leads to the development of resistant strains that no longer respond to treatment. Furthermore, many of the chemical drugs are harmful to the animals being treated, and as larger doses become required due to the build up of resistance, the side effects become even greater. It is particularly difficult to develop vaccines against parasite infections both because of the complexity of the parasite's life cycle and because, while administration of parasites or parasite antigens can lead to the production of a significant antibody response, the immune response is typically not sufficient to protect the animal against infection. As for most parasites, the life cycle of Dirofilaria i mitlε , the helminth that causes heartworm, includes a variety of life forms, each of which presents different targets, and challenges, for immunization. Adult forms of the parasite are quite large and preferentially inhabit the heart and pulmonary arteries of an animal. Sexually mature adults, after mating, produce microfilariae which traverse capillary beds and circulate in the vascular system. The microfilariae are ingested by female mosquitos during blood feeding on an infected dog, subsequent development of the microfilariae into two larval stages (LI and L2) occurs in the mosquito. The microfilariae go through and finally become mature third stage larvae (L3) which can then be transmitted back to a dog through the bite of the mosquito. It is this L3 stage, therefore, that accounts for the initial infection. As early as three days after infection, the L3 molt to the fourth larval (L4) stage, and subsequently to the fifth stage, or immature adults. The immature adults migrate to the heart and pulmonary arteries, where they mature and reproduce, thus producing the microfilariae in the blood. "Occult" infection with heartworm in dogs is defined as an infection in which no microfilariae can be detected, but the existence of adult heartworms can be determined through thoracic examination. Both the molting process and tissue migration are likely to involve the action of one or more enzymes, including proteases. Although protease activity has been identified in a number of parasites (including in larval excretory-secretory products) as well as in mammals, there has been no identification of a cysteine protease gene in any filariid nematode. Cysteine protease genes have been isolated from several mammalian sources and from the nematodes Haemonchus contort s (e.g., Pratt et al., 1992, Mol . Biochem. Parasitol . 51 , 209-218) and Caenorhabditis elegans (Ray et al., 1992, Λfσl. Biochem . Parasitol . 51 , 239-250) . In addition, consensus sequences, particularly around the active sites, have also been identified for serine and cysteine proteases; see, for example, Sakanari et al., 1989, Proc. Natl . Acad. Sci . USA 86 , 4863-4867. The determination of these sequences, however, does not necessarily predict that the cloning of novel cysteine protease genes will be straight-forward, particularly since the sequences shared by different cysteine proteases are such that probes and primers based on the consensus sequences are highly degenerative. Heartworm not only is a major problem in dogs, which typically are unable to develop immunity after infection (i.e., dogs can become reinfected even after being cured by chemotherapy) , but is also becoming increasingly widespread in other companion animals, such as cats and ferrets. Heartworm infections have also been reported in humans. Other parasite infections are also widespread, and all require better treatment, including preventative vaccine programs and/or targeted drug therapies. SUMMARY OF THE INVENTION One embodiment of the present invention relates to an isolated filariid nematode larval nucleic acid molecule that hybridizes, under stringent hybridization conditions, with a Dirofilaria immitis L3 larval cysteine protease gene and/or an Onchocerca volvulus L3 larval cysteine protease gene. A preferred nucleic acid molecule of the present invention includes at least a portion of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, or an allelic variant of one or more of those nucleic acid sequences. The present invention also includes recombinant molecules and recombinant cells that include filariid nematode cysteine protease nucleic acid molecules of the present invention. Also included are methods to produce such nucleic acid molecules, recombinant molecules and recombinant cells of the present invention. Another embodiment of the present invention is an isolated protein that includes a filariid nematode larval cysteine protease protein or a mimetope of such a protein. A filariid nematode cysteine protease protein of the present invention preferably has cysteine protease activity and/or comprises a protein that, when administered to an animal, is capable of eliciting an immune response against a natural helminth cysteine protease protein. The present invention also includes inhibitors of cysteine protease activity as well as antibodies that recognize (i.e., selectively bind to) a filariid nematode cysteine protease protein and/or mimetope thereof of the present invention. Also included are methods to produce such proteins, inhibitors and antibodies of the present invention. Yet another embodiment of the present invention is a therapeutic composition capable of protecting an animal from disease caused by a parasitic helminth. Such a therapeutic composition comprises at least one of the following protective compounds: an isolated parasitic filariid nematode larval nucleic acid molecule that hybridizes under stringent hybridization conditions with a Dirofilaria immitis L3 larval cysteine protease gene and/or an Onchocerca volvulus L3 larval cysteine protease gene; an isolated filariid nematode larval cysteine protease protein or a mimetope thereof; an isolated antibody that selectively binds to a filariid nematode L3 larval cysteine protease protein; and an inhibitor of cysteine protease activity identified by its ability to inhibit filariid nematode L3 larval cysteine protease activity. Also included is a method to protect an animal from disease caused by a parasitic helminth that includes administering to the animal a therapeutic composition of the present invention. A preferred therapeutic composition of the present invention is a composition capable of protecting an animal from heartworm. The present invention also includes a method to identify a compound capable of inhibiting cysteine protease activity of a parasitic helminth. Such a method includes (a) contacting an isolated filariid nematode larval cysteine protease protein with a putative inhibitory compound under conditions in which, in the absence of the compound, the protein has cysteine protease activity; and (b) determining if the putative inhibitory compound inhibits the activity. Also included is a test kit to identify a compound capable of inhibiting cysteine protease activity that includes an isolated filariid nematode larval cysteine protease protein having cysteine protease activity and a means for determining the extent of inhibition of cysteine protease activity in the presence of a putative inhibitory compound. DETAILED DESCRIPTION OF THE INVENTION The present invention provides for filariid nematode L3 larval cysteine protease proteins and nucleic acid molecules, as well as, antibodies directed against filariid nematode L3 larval cysteine protease proteins. Also included in the present invention is the use of these proteins, nucleic acid molecules and antibodies as therapeutic compositions to treat parasitic helminth diseases as well as in other applications, such as those disclosed below. One embodiment of the present invention is an isolated filariid nematode L3 larval cysteine protease protein. A cysteine protease is referred to herein as "CP." A CP that can be found in third stage larvae (L3) is referred to herein as L3 larval CP. That such a protease is referred to as an L3 larval protease does not preclude that protease from also being present in other life stages of a helminth. Indeed, D. immitis L3 CP is also found in fourth stage larvae (L4) , suggesting that L3 CP's of the present invention, in general, can also be found in L4. Furthermore, the inventors discovered that immune dog serum prepared as disclosed in PCT Patent Publication No. WO 92/13560, published August 20, 1992, selectively binds to larval CP's of the present invention, a finding that enabled isolation of the first filariid nematode CP nucleic acid molecule. According to the present invention, an isolated, or biologically pure, protein, is a protein that has been removed from its natural milieu. As such, "isolated" and "biologically pure" do not necessarily reflect the extent to which the protein has been purified. An isolated CP protein of the present invention can be obtained from its natural source, can be produced using recombinant DNA technology or can be produced by chemical synthesis. As used herein, an isolated CP protein of the present invention can be a full-length protein or any homologue of such a protein. Examples of CP homologues include CP proteins in which amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide) , inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitoylation, amidation and/or addition of glycerophosphatidyl inositol) such that the homologue includes at least one epitope capable of eliciting an immune response against a CP protein of the present invention. That is, when the homologue is administered to an animal as an immunogen, using techniques known to those skilled in the art, the animal will produce a humoral and/or cellular immune response against at least one epitope of a CP protein of the present invention. The ability of a protein to effect an immune response, can be measured using techniques known to those skilled in the art. Homologues of CP proteins of the present invention can be the result of natural allelic variation or natural mutation. CP protein homologues of the present invention can also be produced using techniques known in the art including, but not limited to, direct modifications to the protein or modifications to the gene encoding the protein using, for example, classic or recombinant DNA techniques to effect random or targeted mutagenesis. Isolated proteins of the present invention, including homologues, can be identified in a straight-forward manner by the proteins' ability to elicit an immune response against filariid nematode CP proteins. CP proteins of the present invention, including homologues of the full-length protein, have the further characteristic of being encoded by nucleic acid molecules that hybridize under stringent hybridization conditions to at least one of the following genes: (a a gene encoding a Dirofilaria immitis L3 cysteine protease protein (i.e., a D. immitis CP gene); and (b) a gene encoding an Onchocerca volvulus L3 cysteine protease protein (i.e., an O. volvulus CP gene). It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, a gene refers to one or more genes or at least one gene. As such, the terms "a" (or "an") , "one or more" and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising" , "including" , and "having" can be used interchangeably. As used herein, stringent hybridization conditions refer to standard hybridization conditions under which nucleic acid molecules, including oligonucleotides, are used to identify molecules having similar nucleic acid sequences. Such standard conditions are disclosed, for example, in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Labs Press. Examples of such conditions are provided in the Examples section of the present application. Stringent hybridization conditions typically permit isolation of nucleic acid molecules having at least about 70% nucleic acid sequence identity with the nucleic acid molecule being used as a probe in the hybridization reaction. Formulae to calculate the appropriate hybridization and wash conditions to achieve hybridization permitting 30% or less mis-match between two nucleic acid molecules are disclosed, for example, in Meinkoth et al, 1984, Anal. Biochem 138 , 267-284; Meinkoth et al, ibid, is incorporated by reference herein in its entirety. As used herein, a D. immitis CP gene includes all nucleic acid sequences related to a natural D. immitis CP gene such as regulatory regions that control production of the D. immitis CP protein encoded by that gene (such as, but not limited to, transcription, translation or post-translation control regions) as well as the coding region itself. In one embodiment, a D. immitis CP gene includes the nucleic acid sequence SEQ ID NO:l and/or SEQ ID NO:25. Nucleic acid sequence SEQ ID NO:l represents the deduced sequence of a cDNA (complementary DNA) nucleic acid molecule denoted herein as nDiCP 129a , the production of which is disclosed in the Examples. The complement of SEQ ID NO:l (represented herein by SEQ ID NO:25) refers to the nucleic acid sequence of the strand complementary to the strand having SEQ ID N0:l, which can easily be determined by those skilled in the art. Likewise, a nucleic acid sequence complement of any nucleic acid sequence of the present invention refers to the nucleic acid sequence of the nucleic acid strand that is complementary to (i.e., can form a double helix with) the strand for which the sequence is cited. It should be noted that since nucleic acid sequencing technology is not entirely error-free, SEQ ID NO:l (as well as other nucleic acid and protein sequences presented herein) , at best, represents an apparent nucleic acid sequence of the nucleic acid molecule encoding a D. immitiε CP protein of the present invention. In another embodiment, a D. immitis CP gene can be an allelic variant that includes a similar but not identical sequence to SEQ ID NO:l and/or SEQ ID NO:25. An allelic variant of a 17. immitis CP gene including SEQ ID NO:l and/or SEQ ID NO:25 is a gene that occurs at essentially the same locus (or loci) in the genome as the gene including SEQ ID NO:l and/or SEQ ID NO:25, but which, due to natural variations caused by, for example, mutation or recombination, has a similar but not identical sequence. Allelic variants typically encode proteins having similar activity to that of the protein encoded by the gene to which they are being compared. Allelic variants can also comprise alterations in the 5' or 3' untranslated regions of the gene (e.g. , in regulatory control regions) . Allelic variants are well known to those skilled in the art and would be expected to be found within a given parasitic helminth since the genome is diploid and/or among a group of two or more filariid nematodes. Similarly, an O . volvulus CP gene includes all nucleic acid sequences related to a natural O. volvulus CP gene such as regulatory regions that control production of the O . volvulus CP protein encoded by that gene as well as the coding region itself. In one embodiment, an O. volvulus CP gene includes the nucleic acid sequence SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:27 and/or SEQ ID NO:29. Nucleic acid sequence SEQ ID NO:5 represents the deduced sequence of a cDNA (complementary DNA) nucleic acid molecule denoted herein as nOvCP 291 , the production of which is disclosed in the Examples. The complement of SEQ ID NO:5 is referred to herein as SEQ ID NO:27. Nucleic acid sequence SEQ ID NO:14 represents the deduced sequence of a PCR nucleic acid molecule denoted herein as nOvCP 1306 , the production of which is disclosed in the Examples. The complement of SEQ ID NO:14 is referred to herein as SEQ ID NO:29. In another embodiment, an O. volvulus CP gene can be an allelic variant that includes a similar but not identical sequence to SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:27 and/or SEQ ID NO:29. The minimal size of a CP protein homologue of the present invention is a size sufficient to be encoded by a nucleic acid molecule capable of forming a stable hybrid with the complementary sequence of a nucleic acid molecule encoding the corresponding natural protein. As such, the size of the nucleic acid molecule encoding such a protein homologue is dependent on nucleic acid composition and percent homology between the nucleic acid molecule and complementary sequence as well as upon hybridization conditions per se (e.g., temperature, salt concentration, and formamide concentration) . It should also be noted that the extent of homology required to form a stable hybrid can vary depending on whether the homologous sequences are interspersed throughout the nucleic acid molecules or are clustered (i.e., localized) in distinct regions on the nucleic acid molecules. The minimal size of such nucleic acid molecules is typically at least about 12 to about 15 nucleotides in length if the nucleic acid molecules are GC-rich and at least about 15 to about 17 bases in length if they are AT-rich. As such, the minimal size of a nucleic acid molecule used to encode a CP protein homologue of the present invention is from about 12 to about 18 nucleotides in length. There is no limit, other than a practical limit, on the maximal size of such a nucleic acid molecule in that the nucleic acid molecule can include a portion of a gene, an entire gene, or multiple genes, or portions thereof. Similarly, the minimal size of a CP protein homologue of the present invention is from about 4 to about 6 amino acids in length, with preferred sizes depending on whether a full-length, fusion, multivalent, or functional portions of such proteins are desired. Protein homologues of the present invention preferably are capable of eliciting an immune response against a filariid nematode CP protein; of selectively binding to immune serum using techniques as disclosed in PCT Patent Publication No. WO 92/13560 (ibid. ) ; and/or of having cysteine protease activity. The minimum size of a protein capable of eliciting an immune response is a minimum size sufficient to form an epitope, a size that typically is at least from about 5 to about 9 amino acids. As is appreciated by those skilled in the art, an epitope can include amino acids that naturally are contiguous to each other as well as amino acids that, due to the tertiary structure of the natural protein, are in sufficiently close proximity to form an epitope. Methods to measure an immune response or cysteine protease activity are known to those of skill in the art. Any filariid nematode CP protein is a suitable CP protein of the present invention. Suitable filariid nematodes from which to isolate CP proteins (including isolation of the natural protein or production of the protein by recombinant or synthetic techniques) include, but are not limited to, filariid nematodes of the genera Dirofilaria, Onchocerca, Acanthocheilonema , Brugia , Dipetalonema , Loa , Parafilaria , Setaria , Stephanofilaria and Wuchereria . Preferred filariid nematodes include nematodes of the genera Dirofilaria and Onchocerca , with 17. immitis, the parasite that causes heartworm, and O. volvulus , the parasite that causes onchocerciasis, being . more preferred. A preferred filariid nematode CP protein of the present invention is a compound that when administered to an animal in an effective manner, is capable of protecting that animal from disease caused by a parasitic helminth. As such, the parasitic helminth is essentially incapable of causing disease in an animal that is immunized with a filariid nematode CP protein of the present invention. In accordance with the present invention, the ability of a CP protein of the present invention to protect an animal from disease by a parasitic helminth refers to the ability of that protein to treat, ameliorate and/or prevent disease, including infection leading to disease, caused by the parasitic helminth, preferably by eliciting an immune response against the parasitic helminth. Such an immune response can include humoral and/or cellular immune responses. Suitable parasites to target include any parasite that is susceptible to inhibition of cysteine protease activity. In one embodiment, such a parasite is essentially incapable of causing disease in an animal administered a CP protein of the present invention. As such, a parasite to target includes any parasite that produces a protein having one or more epitopes that can be targeted by a humoral and/or cellular immune response against a CP protein of the present invention and/or that can be targeted by a compound that otherwise inhibits CP activity, thereby resulting in the reduced ability of the parasite to cause disease in an animal. Suitable and preferred parasites to target include those parasitic helminths disclosed above as being useful in the production of filariid nematode proteins of the present invention. Additional suitable and preferred parasitic helminths to target are listed elsewhere herein. It is to be appreciated that the present invention also includes mimetopes of CP proteins of the present invention that can be used in accordance with methods as disclosed for CP proteins of the present invention. As used herein, a mimetope of a CP protein of the present invention refers to any compound that is able to mimic the activity of such a CP protein, often because the mimetope has a structure that mimics the CP protein.. Mimetopes can be, but are not limited to: peptides that have been modified to decrease their susceptibility to degradation; anti-idiotypic and/or catalytic antibodies, or fragments thereof; non-proteinaceous immunogenic portions of an isolated protein (e.g., carbohydrate structures) ; and synthetic or natural organic molecules, including nucleic acids. Such mimetopes can be designed using computer-generated structures of proteins of the present invention. Mimetopes can also be obtained by generating random samples of molecules, such as oligonucleotides, peptides or other organic molecules, and screening such samples by affinity chromatography techniques using the corresponding binding partner. One embodiment of the present invention is a fusion protein that includes a filariid nematode CP protein- containing domain attached to a fusion segment. Inclusion of a fusion segment as part of a CP protein of the present invention can enhance the protein's stability during production, storage and/or use. Depending on the segment's characteristics, a fusion segment can also act as an immunopotentiator to enhance the immune response mounted by an animal immunized with a filariid nematode CP protein containing such a fusion segment. Furthermore, a fusion segment can function as a tool to simplify purification of a filariid nematode CP protein, such as to enable purification of the resultant fusion protein using affinity chromatography. A suitable fusion segment can be a domain of any size that has the desired function (e.g. , imparts increased stability, imparts increased immunogenicity to a protein, and/or simplifies purification of a protein) . It is within the scope of the present invention to use one or more fusion segments. Fusion segments can be joined to amino and/or carboxyl termini of the CP-containing domain of the protein. Linkages between fusion segments and CP-containing domains of fusion proteins can be susceptible to cleavage in order to enable straight-forward recovery of the CP- containing domains of such proteins. Fusion proteins are preferably produced by culturing a recombinant cell transformed with a fusion nucleic acid molecule that encodes a protein including the fusion segment attached to either the carboxyl and/or amino terminal end of a CP- containing domain. Preferred fusion segments for use in the present invention include a glutathione binding domain, such as Schistosoma japonicum glutathione-S-transferase (GST) or a portion thereof capable of binding to glutathione; a metal binding domain, such as a poly-histidine segment capable of binding to a divalent metal ion; an immunoglobulin binding domain, such as Protein A, Protein G, T cell, B cell, Fc receptor or complement protein antibody-binding domains; a sugar binding domain such as a maltose binding domain from a maltose binding protein; and/or a "tag" domain (e.g., at least ' a portion of β- galactosidase, a strep tag peptide, other domains that can be purified using compounds that bind to the domain, such as monoclonal antibodies) . More preferred fusion segments include metal binding domains, such as a poly¬ histidine segment; a maltose binding domain; a strep tag peptide, such as that available from Bio etra in Tampa, FL; and an S10 peptide. An example of a particularly preferred fusion protein of the present invention is PHIS-PDiCP 314 and PHIS-POvCP 401 production of which is disclosed herein. Another embodiment of the present invention is a filariid nematode CP protein that also includes at least one additional protein segment that is capable of protecting an animal from one or more diseases. Such a multivalent protective protein can be produced by culturing a cell transformed with a nucleic acid molecule comprising two or more nucleic acid domains joined together in such a manner that the resulting nucleic acid molecule is expressed as a multivalent protective compound containing at least two protective compounds, or portions thereof, capable of protecting an animal from diseases caused, for example, by at least one infectious agent. Examples of multivalent protective compounds include, but are not limited to, a CP protein of the present invention attached to one or more compounds protective against one or more other infectious agents, particularly an agent that infects humans, cats, dogs, cattle and/or horses, such as, but not limited to: viruses (e.g., caliciviruses, distemper viruses, hepatitis viruses, herpesviruses, immunodeficiency viruses, infectious peritonitis viruses, leukemia viruses, panleukopenia viruses, parvoviruses, rabies viruses, other cancer-causing or cancer-related viruses) ; bacteria (e.g., Leptospira , Rochalimaea) ; fungi and fungal-related microorganisms (e.g., Candida , Cryptococcus , Hiεtoplasma) ; and other parasites (e.g., Babesia , Cryptosporidium, Eimeria , Encephalitozoo , Hepatozoon , Isospora , Micros poridia , Neospora , Nosema , Plasmodium, Pneumocystis , Toxoplasma , as well as helminth parasites, such as those disclosed herein) . In one embodiment, a 17. immitis CP protein of the present invention is attached to one or more additional compounds protective against heartworm. In another embodiment, an O. volvulus CP protein of the present invention is attached to one or more additional compounds protective against onchocerciasis. A preferred filariid nematode CP protein of the present invention is a protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nDiCP 1298 , nucleic acid molecule nθvCP 291 , and/or nOvCP 1306 . Such a CP protein is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having a sequence complementary to nucleic acid sequence SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:14, SEQ ID NO:16; i.e., nucleic acid sequences SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, and/or other sequences disclosed herein. The nucleic acid molecule nDiCP 1298 contains an open reading frame which is represented herein by SEQ ID NO:l. The open reading frame in nDiCP 1298 (SEQ ID NO:l) extends from the first nucleotide up to the stop codon beginning at about nucleotide 1195 and encodes a protein of about 398 amino acids, denoted herein as PDiCP 398 , the deduced amino acid sequence of which is represented herein as SEQ ID NO:2. The sequence represented by SEQ ID NO:l suggests that an initiating methionine (ATG) may be located at about nucleotides 97 through 99. Assuming that this ATG represents the initiation (start) codon and that nucleotides 1195 through about nucleotide 1197 of SEQ ID NO:l represent the termination (stop) codon, then SEQ ID NO:l encodes a full-length D. immitis CP protein having an amino acid sequence of about 366 amino acids, denoted herein as PDiCP 366 . That open reading frame is denoted herein as nucleic acid molecule nDiCP 1098 which spans from about nucleotide 97 through about nucleotide 1194 Of SEQ ID NO:l. Comparison of amino acid sequence SEQ ID NO:2 with amino acid sequences reported in GenBank indicates that the significant homology started at about amino acid 85 of SEQ ID NO:2, corresponding to an ATG codon in SEQ ID NO:l spanning from about nucleotide 253 through about nucleotide 255. While not being bound by theory, this comparison suggests that the mature 17. immitis cysteine protease is a protein of about 314 amino acids, denoted herein as PDiCP 3 , which has the deduced amino acid sequence represented herein as SEQ ID NO:4. PDiCP 3H is encoded by a nucleic acid molecule of about 942 nucleotides, denoted herein as nDiCP 942 , the nucleic acid sequence of which is represented herein as SEQ ID NO:3, which corresponds to a region spanning from about nucleotide 253 through about nucleotide 1194 of SEQ ID NO:l. Based on SEQ ID NO:4, PDiCP 314 has a calculated molecular weight of about 36.2 kD and an estimated pi of 9.36. The nucleic acid molecule nOvCP 291 contains an open reading frame which is represented herein by SEQ ID NO:5. The open reading frame in nOvCP 291 (SEQ ID NO:5) extends from about the second nucleotide up to the stop codon beginning at about nucleotide 218 and encodes a protein of about 72 amino acids, denoted herein as POvCP^, the deduced amino acid sequence of which is represented herein as SEQ ID NO:6. The coding region of POvCP^ is encoded by the nucleic acid molecule nOvCP 216 which is represented herein as SEQ ID NO:7. Translation of SEQ ID NO:14 suggests that nucleic acid molecule nOvCP 1306 encodes about 401 amino acids of a O. volvulus cysteine protease protein, which is referred to herein as POvCP 401 , assuming an open reading frame having a termination codon spanning from about nucleotide 20 through about nucleotide 1222 of SEQ ID NO:14. The deduced amino acid sequence of POvCP 401 is represented herein as SEQ ID NO:31. Comparison of amino acid sequence SEQ ID NO:31 with amino acid sequences reported in GenBank indicates that SEQ ID NO:31 is about 44% identical over a region of about 330 amino acids to the amino acid sequence of the rabbit cathepsin K precursor. It is also to be noted that the amino acid sequence of O. volvulus cysteine protease protein POvCP 401 is about 49% identical to the coding region of 17. immitis cysteine protease protein PDiCP 398 . Preferred filariid nematode CP proteins of the present invention also include: proteins comprising amino acid sequences that are at least about 40%, preferably at least about 60%, more preferably at least about 75% and even more preferably at least about 90% identical to amino acid sequence SEQ ID NO:4; proteins comprising an amino acid sequences that are at least about 70%, more preferably at least about 75%, even more preferably at least about 80% and even more preferably at least about 90% identical to amino acid sequence SEQ ID NO:6; and proteins comprising an amino acid sequences that are at least about 45%, more preferably at least about 65%, even more preferably at least about 75% and even more preferably at least about 90% identical to amino acid sequence SEQ ID NO:31. More preferred filariid nematode CP proteins of the present invention include: proteins encoded by at least a portion of SEQ ID NO:l and, as such, have amino acid sequences that include at least a portion of SEQ ID NO:2; proteins encoded by at least a portion of SEQ ID NO:5 and, as such, have amino acid sequences that include at least a portion of SEQ ID NO:6; and proteins encoded by at least a portion of SEQ ID NO:14 and, as such, have amino acid sequences that include at least a portion of SEQ ID NO:15. Particularly preferred filariid nematode CP proteins of the present invention are proteins that include SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:15 and/or SEQ ID NO:31 (including, but not limited to the encoded proteins, full-length proteins, processed proteins, fusion proteins and multivalent proteins) as well as proteins that are truncated homologues of proteins that include SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 SEQ ID NO:15 and/or SEQ ID NO:31. Even more preferred proteins include PDiCP 398 , PDiCP 366 , PDiCP 314 , PDiCP 107l , PHIS-PDiCP 314 , PDiCP 356 , PHIS-PDiCP 945 , POvCP ?2 , POvCP 40 , and PHIS-POvCP 1203 . Examples of methods to produce such proteins are disclosed herein, including in the Examples section. Another embodiment of the present invention is an isolated filariid nematode nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene selected from the group consisting of a 17. immitis L3 larval cysteine protease gene and an O. volvulus L3 larval cysteine protease gene. The identifying characteristics of such genes are heretofore described. A nucleic acid molecule of the present invention can include an isolated natural filariid nematode CP gene or a homologue thereof, the latter of which is described in more detail below. A nucleic acid molecule of the present invention can include one or more regulatory regions, full-length or partial coding regions, or combinations thereof. The minimal size of a nucleic acid molecule of the present invention is the minimal size that can form a stable hybrid with one of the aforementioned genes under stringent hybridization conditions. Suitable and preferred filariid nematodes are disclosed above. In accordance with the present invention, an isolated nucleic acid molecule is a nucleic acid molecule that is not in its natural milieu (i.e., that has been subject to human manipulation) . As such, "isolated" does not reflect the extent to which the nucleic acid molecule has been purified. An isolated nucleic acid molecule can include DNA, RNA, or derivatives of either DNA or RNA. An isolated filariid nematode CP nucleic acid molecule of the present invention can be obtained from its natural source either as an entire (i.e., complete) gene or a portion thereof capable of forming a stable hybrid with that gene. An isolated filariid nematode CP nucleic acid molecule can also be produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification, cloning) or chemical synthesis. Isolated filariid nematode CP nucleic acid molecules include natural nucleic acid molecules and homologues thereof, including, but not limited to, natural allelic variants and modified nucleic acid molecules in which nucleotides have been inserted, deleted, substituted, and/or inverted in such a manner that such modifications do not substantially interfere with the nucleic acid molecule's ability to encode a filariid nematode CP protein of the present invention or to form stable hybrids under stringent conditions with natural gene isolates. A filariid nematode CP nucleic acid molecule homologue can be produced using a number of methods known to those skilled in the art (see, for example, Sambrook et al., ibid.). For example, nucleic acid molecules can be modified using a variety of techniques including, but not limited to, classic mutagenesis techniques and recombinant DNA techniques, such as site-directed mutagenesis, chemical treatment of a nucleic acid molecule to induce mutations, restriction enzyme cleavage of a nucleic acid fragment, ligation of nucleic acid fragments, polymerase chain reaction (PCR) amplification and/or mutagenesis of selected regions of a nucleic acid sequence, synthesis of oligonucleotide mixtures and ligation of mixture groups to "build" a mixture of nucleic acid molecules and combinations thereof. Nucleic acid molecule homologues can be selected from a mixture of modified nucleic acids by screening for the function of the protein encoded by the nucleic acid (e.g., ability to elicit an immune response against at least one epitope of a filariid nematode CP protein) and/or by hybridization with a D. immitis CP gene and/or with an O. volvulus CP gene. An isolated nucleic acid molecule of the present invention can include a nucleic acid sequence that encodes at least one filariid nematode CP protein of the present invention, examples of such proteins being disclosed herein. Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a filariid nematode CP protein. As heretofore disclosed, filariid nematode CP proteins of the present invention include, but are not limited to, proteins having full- length filariid nematode CP coding regions, proteins having partial filariid nematode CP coding regions. fusion proteins, multivalent protective proteins and combinations thereof. A preferred nucleic acid molecule of the present invention, when administered to an animal, is capable of protecting that animal from disease caused by a parasitic helminth. As will be disclosed in more detail below, such a nucleic acid molecule can be, or encode, an antisense RNA, a molecule capable of triple helix formation, a ribozyme, or other nucleic acid-based drug compound. In additional embodiments, a nucleic acid molecule of the present invention can encode a protective protein, the nucleic acid molecule being delivered to the animal by direct injection (i.e, as a naked nucleic acid) or in a vehicle such as a recombinant virus vaccine or a recombinant cell vaccine. One embodiment of the present invention is a filariid nematode CP nucleic acid molecule that hybridizes under stringent hybridization conditions with the nucleic acid sequence nDiCP 1298 the nucleic acid sequence nOvCP 291 , and with the nucleic acid sequence nOvCP 13(J6 . The deduced nucleic acid sequence of nDiCP 1298 is represented herein as SEQ ID NO:l; the deduced nucleic acid sequence of nθvCP 291 , is represented herein as SEQ ID NO:5, and the deduced nucleic acid sequence of nOvCP 1306 , is represented herein as SEQ ID NO:14. An open reading frame contained in nDiCP 1298 is similar to that of known cysteine proteases and is referred to herein as nDiCP 942 , is represented by SEQ ID NO:3. The open reading frame contained in nθvCP 291 referred to herein as nθvCP 216 , is represented by SEQ ID NO:7. The open reading frame contained in nθvCP 1306 referred to herein as nOvCP 1203 , is represented by SEQ ID NO:16. A preferred nucleic acid molecule of the present invention includes at least a portion of nucleic acid sequence SEQ ID NO:l, SEQ ID NO:5, SEQ ID NO:14, SEQ ID NO:25, SEQ ID NO:27 and/or SEQ ID NO:29 that is capable of hybridizing to a D. immitis CP gene and/or to a O. volvulus CP gene of the present invention. More preferred is a nucleic acid molecule that includes nucleic acid sequence SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29 and/or SEQ ID NO:30, or allelic variants thereof. Such a nucleic acid molecule can include nucleotides in addition to those included in the SEQ ID NOs, such as, but not limited to, a full-length gene, a full-length coding region, a nucleic acid molecule encoding a fusion protein, or a nucleic acid molecule encoding a multivalent protective compound. Particularly preferred nucleic acid molecules include nDiCP 1298 nDiCP 1194 nDiCP 1098 nDiCP 942 , nDiCP 945 , nDiCP 850 , nDiCP 450 , nDiCP 1071 , nθvCP 291 , nθvCP 216 , nOvCP 1306 , nOvCP 1272 or nOvCP 1203 . The present invention also includes nucleic acid molecules encoding a protein having at least a portion of SEQ ID NO:2, nucleic acid molecules encoding a protein having at least a portion of SEQ ID NO:4, nucleic acid molecules encoding a protein having at least a portion of SEQ ID NO:6, nucleic acid molecules encoding a protein having at least a portion of SEQ ID NO:15, nucleic acid molecules encoding a protein having at least a portion of SEQ ID NO:31, including nucleic acid molecules that have been modified to accommodate codon usage properties of the cells in which such nucleic acid molecules are to be expressed. Knowing the nucleic acid sequences of certain filariid nematode CP nucleic acid molecules of the present invention allows one skilled in the art to, for example, (a) make copies of those nucleic acid molecules, (b) obtain nucleic acid molecules including at least a portion of such nucleic acid molecules (e.g., nucleic acid molecules including full-length genes, full-length coding regions, regulatory control sequences, truncated coding regions) , and (c) obtain CP nucleic acid molecules for other filariid nematodes, particularly since, as described in detail in the Examples section, knowledge of 17. immitiε CP nucleic acid molecules of the present invention enabled the isolation of O . volvulus CP nucleic acid molecules of the present invention. Such nucleic acid molecules can be obtained in a variety of ways including screening appropriate expression libraries with antibodies of the present invention; traditional cloning techniques using oligonucleotide probes of the present invention to screen appropriate libraries or DNA; and PCR amplification of appropriate libraries or DNA using oligonucleotide primers of the present invention. Preferred libraries to screen or from which to amplify nucleic acid molecule include parasitic helminth L3 larval libraries as well as genomic DNA libraries. Similarly, preferred DNA sources to screen or from which to amplify nucleic acid molecules include parasitic helminth L3 larval DNA and genomic DNA. Techniques to clone and amplify genes are disclosed, for example, in Sambrook et al., ibid. The present invention also includes nucleic acid molecules that are oligonucleotides capable of hybridizing, under stringent hybridization conditions, with complementary regions of other, preferably longer, nucleic acid molecules of the present invention such as those comprising filariid nematode CP genes or other filariid nematode CP nucleic acid molecules. Oligonucleotides of the present invention can be RNA, DNA, or derivatives of either. The minimal size of such oligonucleotides is the size required to form a stable hybrid between a given oligonucleotide and the complementary sequence on another nucleic acid molecule of the present invention. Minimal size characteristics are disclosed herein. The size of the oligonucleotide must also be sufficient for the use of the oligonucleotide in accordance with the present invention. Oligonucleotides of the present invention can be used in a variety of applications including, but not limited to, as probes to identify additional nucleic acid molecules. as primers to amplify or extend nucleic acid molecules or in therapeutic applications to inhibit CP protein production or activity. Such therapeutic applications include the use of such oligonucleotides in, for example, antisense-, triplex formation-, ribozyme- and/or RNA drug-based technologies. The present invention, therefore, includes such oligonucleotides and methods to protect animals ^ from disease caused by parasitic helminths by use of one or more of such technologies. Appropriate oligonucleotide-containing therapeutic compositions can be administered to an animal, using techniques known to those skilled in the art, either prior to or after infection by a parasitic helminth such as D. immitis or O. volvulus in order to protect the animal from disease. The present invention also includes a recombinant vector, which includes at least one filariid nematode CP nucleic acid molecule of the present invention, inserted into any vector capable of delivering the nucleic acid molecule into a host cell. Such a vector contains heterologous nucleic acid sequences, that is nucleic acid sequences that are not naturally found adjacent to nucleic acid molecules of the present invention and that preferably are derived from a species other than the species from which the nucleic acid molecule(s) are derived. The vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a virus or a plasmid. Recombinant vectors can be used in the cloning, sequencing, and/or otherwise manipulating of filariid nematode CP nucleic acid molecules of the present invention. One type of recombinant vector, referred to herein as a recombinant molecule and described in more detail below, can be used in the expression of nucleic acid molecules of the present invention. Preferred recombinant vectors are capable of replicating in the transformed cell. Suitable and preferred nucleic acid molecules to include in recombinant vectors of the present invention are as disclosed herein for suitable and preferred filariid nematode CP nucleic acid molecules per se. Particularly preferred nucleic acid molecules to include in recombinant vectors, and particularly in recombinant molecules, of the present invention include nDiCP 1298 nDiCP 1194( nDiCP 1098j nDiCP 942 , nDiCP 945 , nDiCP 850 , nDiCP 450 , nDiCP 1071 , nOvCP 291 , nOvCP 216 , nOvCP 1306 , nθvCP 1272 and nOvCP 1203 . Isolated filariid nematode CP proteins of the present invention can be produced in a variety of ways, including production and recovery of natural proteins, production and recovery of recombinant proteins, and chemical synthesis of the proteins. In one embodiment, an isolated protein of the present invention is produced by culturing a cell capable of expressing the protein under conditions effective to produce the protein, and recovering the protein. A preferred cell to culture is a recombinant cell that is capable of expressing the protein, the recombinant cell being produced by transforming a host cell with one or more nucleic acid molecules of the present invention. Transformation of a nucleic acid molecule into a cell can be accomplished by any method by which a nucleic acid molecule can be inserted into the cell. Transformation techniques include, but are not limited to, transfection, electroporation, microinjection, lipofection, adsorption, and protoplast fusion. A recombinant cell may remain unicellular or may grow into a tissue, organ or a multicellular organism. Transformed nucleic acid molecules of the present invention can remain extrachromoso al or can integrate into one or more sites within a chromosome of the transformed (i.e., recombinant) cell in such a manner that their ability to be expressed is retained. Suitable and preferred nucleic acid molecules with which to transform a cell are as disclosed herein for suitable and preferred filariid nematode CP nucleic acid molecules per se. Particularly preferred nucleic acid molecules to include in recombinant cells of the present invention include nDiCP 1298j nDiCP 1194ι nDiCP 1098> nDiCP 942 , nDiCP 945 , nDiCP 850 , nDiCP 450 , nDiCP l071 , nOvCP 291 , nOvCP 216 , nOvCP 1306 , nOvCP 1272 and nθvCP 1203 . Suitable host cells to transform include any cell that can be transformed with a nucleic acid molecule of the present invention. Host cells can be either untransformed cells or cells that are already transformed with at least one nucleic acid molecule. Host cells of the present invention either can be endogenously (i.e., naturally) capable of producing filariid nematode CP proteins of the present invention or can be capable of producing such proteins after being transformed with at least one nucleic acid molecule of the present invention. Host cells of the present invention can be any cell capable of producing at least one protein of the present invention, and include bacterial, fungal (including yeast) , parasite (including helminth, protozoa and ectoparasite) , insect, other animal and plant cells. Preferred host cells include bacterial, mycobacterial, yeast, helminth, insect and mammalian cells. More preferred host cells include Salmonella , Escherichia , Bacillus, Listeria, Saccharomyces , Spodoptera, Mycobacteria , Trichoplusia, BHK (baby hamster kidney) cells, MDCK cells (normal dog kidney cell line for canine herpesvirus cultivation) , CRFK cells (normal cat kidney cell line for feline herpesvirus cultivation) , CV-1 cells (African monkey kidney cell line used, for example, to culture raccoon poxvirus) , COS (e.g., COS-7) cells, and Vero cells. Particularly preferred host cells are Escherichia coli , including E. coli K-12 derivatives; Salmonella typhi ; Salmonella typhimurium, including attenuated strains such as UK-1 3987 and SR-11 4072; Spodoptera frugiperda ; Trichoplusia ni ; BHK cells; MDCK cells; CRFK cells; CV-1 cells; COS cells; Vero cells; and non-tumorigenic mouse myoblast G8 cells (e.g., ATCC CRL 1246) . Additional appropriate mammalian cell hosts include other kidney cell lines, other fibroblast cell lines (e.g., human, murine or chicken embryo fibroblast cell lines) , myeloma cell lines, Chinese hamster ovary cells, mouse NIH/3T3 cells, LMTK 31 cells and/or HeLa cells. In one embodiment, the proteins may be expressed as heterologous proteins in myeloma cell lines employing immunoglobulin promoters. A recombinant cell is preferably produced by transforming a host cell with one or more recombinant molecules, each comprising one or more nucleic acid molecules of the present invention operatively linked to an expression vector containing one or more transcription control sequences. The phrase operatively linked refers to insertion of a nucleic acid molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell. As used herein, an expression vector is a DNA or RNA vector that is capable of transforming a host cell and of effecting expression of a specified nucleic acid molecule. Preferably, the expression vector is also capable of replicating within the host cell. Expression vectors can be either prokaryotic or eukaryotic, and are typically viruses or plasmids. Expression vectors of the present invention include any vectors that function (i.e., direct gene expression) in recombinant cells of the present invention, including in bacterial, fungal, parasite, insect, other animal, and plant cells. Preferred expression vectors of the present invention can direct gene expression in bacterial, yeast, helminth or other parasite, insect and mammalian cells and more preferably in the cell types heretofore disclosed. Recombinant molecules of the present invention may also (a) contain secretory signals (i.e., signal segment nucleic acid sequences) to enable an expressed filariid nematode CP protein of the present invention to be secreted from the cell that produces the protein and/or (b) contain fusion sequences which lead to the expression of nucleic acid molecules of the present invention as fusion proteins. Examples of suitable signal segments and fusion segments encoded by fusion segment nucleic acids are disclosed herein. Eukaryotic recombinant molecules may include intervening and/or untranslated sequences surrounding and/or within the nucleic acid sequences of nucleic acid molecules of the present invention. Suitable signal segments include natural signal segments or any heterologous signal segment capable of directing the secretion of a protein of the present invention. Preferred signal segments include, but are not limited to, tissue plasminogen activator (t-PA) , interferon, interleukin, growth hormone, histocompatibility and viral envelope glycoprotein signal segments. Nucleic acid molecules of the present invention can be operatively linked to expression vectors containing regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell and that control the expression of nucleic acid molecules of the present invention. In particular, recombinant molecules of the present invention include transcription control sequences. Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences. Suitable transcription control sequences include any transcription control sequence that can function in at least one of the recombinant cells of the present invention. A variety of such transcription control sequences are known to those skilled in the art. Preferred transcription control sequences include those which function in bacterial, yeast, helminth or other parasite, insect and mammalian cells, such as, but not limited to, tac, lac, trp, trc, oxy-pro, omp/lpp, rrnB, bacteriophage lambda (such as lambdap L and lambdap R and fusions that include such promoters) , bacteriophage T7, T71ac, bacteriophage T3, bacteriophage SP6, bacteriophage SP01, metallothionein, alpha-mating factor, Pichia alcohol oxidase, alphavirus subgenomic promoters (such as Sindbis virus subgenomic promoters) , antibiotic resistance gene, baculovirus, Heliothis zea insect virus, vaccinia virus, herpesvirus, poxvirus, adenovirus, cytomegalovirus (such as intermediate early promoters, simian virus 40, retrovirus, actin, retroviral long terminal repeat, Rous sarcoma virus, heat shock, phosphate and nitrate transcription control sequences as well as other sequences capable of controlling gene expression in prokaryotic or eukaryotic cells. Additional suitable transcription control sequences include tissue-specific promoters and enhancers as well as lymphokine-inducible promoters (e.g. , promoters inducible by interferons or interleukins) . Transcription control sequences of the present invention can also include naturally occurring transcription control sequences naturally associated with a filariid nematode nucleic acid molecule, such as a 17. immitiε or O. volvuluε molecule prior to isolation. A recombinant molecule of the present invention is a molecule that can include at least one of any nucleic acid molecule heretofore described operatively linked to at least one of any transcription control sequence capable of effectively regulating expression of the nucleic acid molecule(s) in the cell to be transformed, examples of which are disclosed herein. Particularly preferred recombinant molecules include, p?gal-nDiCP 1298 pHis-nDiCP 945 , pVL1393-nDiCP 945 , vBV-nDiCP 945 , pkB3poly- nDiCP 1071 , Rcn-nDiCP 1071 , pll-nDiCP 1071 /pSyn-nDiPLA2 453 , Rcn- nDiCP 1071 -nDiPLA2 453 , pCMV-nDiCP 1071 , pBSC-nDiCP 356 , and pHis- nOvCP 1203 . Details regarding the production of D. immitis and O. volvulus CP nucleic acid molecule-containing recombinant molecules are disclosed herein. A recombinant cell of the present invention includes any cell transformed with at least one of any nucleic acid molecule of the present invention. Suitable and preferred nucleic acid molecules as well as suitable and preferred recombinant molecules with which to transfer cells are disclosed herein. Particularly preferred recombinant cells include E. coli;pHis-nDiCP 945 , S. .fruςriperda:pVL1393-nDiCP 945 , BSCl:pKB3poly-nDiCP 107l , BHK:pCMV-nDiCP 107l , BSCl:pll-nDiCP 1071 /pSyn-nDiPLA2 453 and E.. Coli:pHis-nOvCP 1203 . Details regarding the production of these recombinant cells are disclosed herein. Recombinant cells of the present invention can also be co-transformed with one or more recombinant molecules including filariid nematode CP nucleic acid molecules encoding one or more proteins of the present invention and one or more other proteins useful in the production of multivalent vaccines which can include one or more protective compounds. It may be appreciated by one skilled in the art that use of recombinant DNA technologies can improve expression of transformed nucleic acid molecules by manipulating, for example, the number of copies of the nucleic acid molecules within a host cell, the efficiency with which those nucleic acid molecules are transcribed, the efficiency with which the resultant transcripts are translated, and the efficiency of post-translational modifications. Recombinant techniques useful for increasing the expression of nucleic acid molecules of the present invention include, but are not limited to, operatively linking nucleic acid molecules to high-copy number plasmids, integration of the nucleic acid molecules into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals (e.g., ribosome binding sites, Shine-Dalgarno sequences) , modification of nucleic acid molecules of the present invention to correspond to the codon usage of the host cell, deletion of sequences that destabilize transcripts, and use of control signals that temporally separate recombinant cell growth from recombinant enzyme production during fermentation. The activity of an expressed recombinant protein of the present invention may be improved by fragmenting, modifying, or derivatizing nucleic acid molecules encoding such a protein. In accordance with the present invention, recombinant cells of the present invention can be used to produce one or more proteins of the present invention by culturing such cells under conditions effective to produce such a protein, and recovering the protein. Effective conditions to produce a protein include, but are not limited to, appropriate media, bioreactor, temperature, pH and oxygen conditions that permit protein production. An appropriate, or effective, medium refers to any medium in which a cell of the present invention, when cultured, is capable of producing a filariid nematode CP protein of the present invention. Such a medium is typically an aqueous medium comprising assimilable carbon, nitrogen and phosphate sources, as well as appropriate salts, minerals, metals and other nutrients, such as vitamins. The medium may comprise complex nutrients or may be a defined- minimal medium. Cells of the present invention can be cultured in conventional fermentation bioreactors, which include, but are not limited to, batch, fed-batch, cell recycle, and continuous fermentors. Culturing can also be conducted in shake flasks, test tubes, microtiter dishes, and petri plates. Culturing is carried out at a temperature, pH and oxygen content appropriate for the recombinant cell. Such culturing conditions are well within the expertise of one of ordinary skill in the art. Examples of suitable conditions are included in the Examples section. Depending on the vector and host system used for production, resultant proteins of the present invention may either remain within the recombinant cell; be secreted into the fermentation medium; be secreted into a space between two cellular membranes, such as the periplasmic space in E. coli ; or be retained on the outer surface of a cell or viral membrane. The phrase "recovering the protein" refers simply to collecting the whole fermentation medium containing the protein and need not imply additional steps of separation or purification. Proteins of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization. Proteins of the present invention are preferably retrieved in "substantially pure" form. As used herein, "substantially pure" refers to a purity that allows for the effective use of the protein as a therapeutic composition or diagnostic. A therapeutic composition for animals, for example, should exhibit no substantial toxicity and should be capable of stimulating the production of antibodies in a treated animal. The present invention also includes isolated antibodies capable of selectively binding to a filariid nematode CP protein of the present invention or to a mimetope thereof. Such antibodies are also referred to herein as anti-filariid nematode CP antibodies. Particularly preferred antibodies of this embodiment include anti-D. immitis CP antibodies and anti-O. volvulus CP antibodies. Isolated antibodies are antibodies that have been removed from their natural milieu. The term "isolated" does not refer to the state of purity of such antibodies. As such, isolated antibodies can include anti-sera containing such antibodies, or antibodies that have been purified to varying degrees. As used herein, the term "selectively binds to" refers to the ability of antibodies of the present invention to preferentially bind to specified proteins and mimetopes thereof of the present invention. Binding can be measured using a variety of methods known to those skilled in the art including immunoblot assays, immunoprecipitation assays, radioimmunoassays, enzyme immunoassays (e.g., ELISA), immunofluorescent antibody assays and immunoelectron microscopy; see, for example, Sambrook et al., ibid. An anti-filariid nematode CP antibody preferably binds to a filariid nematode CP protein in such a way as to reduce the activity of that protein. Antibodies of the present invention can be either polyclonal or monoclonal antibodies. Antibodies of the present invention include functional equivalents such as antibody fragments and genetically-engineered antibodies, including single chain antibodies, that are capable of selectively binding to at least one of the epitopes of the protein or mimetope used to obtain the antibodies. Antibodies of the present invention also include chimeric antibodies that can bind to more than one epitope. Preferred antibodies are raised in response to proteins, or mimetopes thereof, that are encoded, at least in part, by a nucleic acid molecule of the present invention. A preferred method to produce antibodies of the present invention includes (a) administering to an animal an effective amount of a protein or mimetope thereof of the present invention to produce the antibodies and (b) recovering the antibodies. In another method, antibodies of the present invention are produced recombinantly using techniques as heretofore disclosed to produce filariid nematode CP proteins of the present invention. Antibodies raised against defined proteins or mimetopes can be advantageous because such, antibodies are not substantially contaminated with antibodies against other substances that might otherwise cause interference in a diagnostic assay or side effects if used in a therapeutic composition. Antibodies of the present invention have a variety of potential uses that are within the scope of the present invention. For example, such antibodies can be used (a) as therapeutic compounds to passively immunize an animal in order to protect the animal from parasitic helminths susceptible to treatment by such antibodies, (b) as reagents in assays to detect infection by such filariid nematodes and/or (c) as tools to screen expression libraries and/or to recover desired proteins of the present invention from a mixture of proteins and other contaminants. Furthermore, antibodies of the present invention can be used to target cytotoxic agents to parasitic helminths of the present invention in order to directly kill such helminths. Targeting can be accomplished by conjugating (i.e., stably joining) such antibodies to the cytotoxic agents using techniques known to those skilled in the art. Suitable cytotoxic agents are known to those skilled in the art. One embodiment of the present invention is a therapeutic composition that, when administered to an animal in an effective manner, is capable of protecting that animal from disease caused by a parasitic helminth. Therapeutic compositions of the present invention include at least one of the following protective compounds: (a) an isolated filariid nematode L3 larval cysteine protease protein or a mimetope thereof; (b) an isolated filariid nematode nucleic acid molecule that hybridizes under stringent hybridization conditions with a 17. immitiε L3 larval cysteine protease gene and/or an O. volvuluε L3 larval cysteine protease gene; (c) an isolated antibody that selectively binds to a filariid nematode L3 larval cysteine protease protein; (d) an inhibitor af cysteine protease activity identified by its ability to inhibit filariid nematode L3 larval cysteine protease activity; and (e) a mixture (i.e., combination) of at least two of the compounds. As used herein, a protective compound refers to a compound that, when administered to an animal in an effective manner, is able to treat, ameliorate, and/or prevent disease caused by a parasitic helminth of the present invention. Suitable helminths to target include a parasite comprises a tissue-migrating helminth. Preferred helminths to target include, for example, nematodes, cestodes and trematodes. More preferred helminths to target include, for example, filariid, ascarid, strongyle and trichostrongyle nematodes. Even more preferred helminths to target include, for example, nematodes of the genera Acanthocheilonema , Aelurostrongylus , Ancylostoma , Angioεtrongyluε , Ascaris , Brugia , Bunostomum, Dictyocaulus , Dioctophyme, Dipetalonema , Dirofilaria, Dracunculus, Filaroideε , Lagochilascaris , Loa , Mansonella , Muelleriuε , Necator, Onchocerca , Parafilaria , Paraεcariε , Protostrongyluε , Setaria, Stephanofilaria , Strongyloides , Strongylus, Thelazia , Toxaεcariε, Toxocara , Trichinella , ϋncinaria and Wuchereria. Other particularly preferred parasitic helminths include nematodes of the genera Capillaria, Chabertia, Cooperia , Enterobiu , Haemonchuε, Nematodiruε , Oesophagostomu , Ostertagia , Trichostrongyluε and Trichuris. Particularly preferred nematodes include Dirofilaria , Onchocerca , Acanthocheilonema , Brugia , Dipetalonema , Loa , Parafilaria, Setaria , Stephanofilaria and Wuchereria filariid nematodes, with Dirofilaria and Onchocerca being more preferred. Examples of proteins, nucleic acid molecules and antibodies of the present invention are disclosed herein. The present invention also includes a therapeutic composition comprising at least one filariid nematode CP- based compound of the present invention in combination with at least one additional compound protective against one or more infectious agents. Examples of such compounds and infectious agents are disclosed herein. Therapeutic compositions of the present invention can be administered to any animal susceptible to such therapy, preferably to mammals, and more preferably to dogs, cats, humans, ferrets, horses, cattle, sheep and other pets, economic food animals and/or zoo animals. Preferred animals to protect against heartworm include dogs, cats, humans and ferrets, with dogs and cats being particularly preferred. Preferred animals to protect against onchocerciasis include humans, cattle and horses, with humans being particularly preferred. In one embodiment, a therapeutic composition of the present invention can be administered to the vector in which the parasitic helminth develops, such as to a mosquito in order to prevent the spread of heartworm or to a black fly in order to prevent the spread of onchocerciasis. Such administration could be orally or by developing transgenic vectors capable of producing at least one therapeutic composition of the present invention. In another embodiment, a vector, such as a mosquito or a black fly, can ingest therapeutic compositions present in the blood of a host that has been administered a therapeutic composition of the present invention. Therapeutic compositions of the present invention can be formulated in an excipient that the animal to be treated can tolerate. Examples of such excipients include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Nonaqueous vehicles, such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used. Other useful formulations include suspensions containing viscosity enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservatives include thimerosal, - or o-cresol, formalin and benzyl alcohol. Standard formulations can either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection. Thus, in a non- liquid formulation, the excipient can comprise dextrose, human serum albumin, preservatives, etc., to which sterile water or saline can be added prior to administration. In one embodiment of the present invention, the therapeutic composition can also include an immunopotentiator, such as an adjuvant or a carrier. Adjuvants are typically substances that generally enhance the immune response of an animal to a specific antigen. Suitable adjuvants include, but are not limited to, Freund's adjuvant; other bacterial cell wall components; aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins; viral coat proteins; other bacterial-derived preparations; gamma interferon; block copolymer adjuvants, such as Hunter's Titermax™ adjuvant (Vaxcel™ , Inc. Norcross, GA) ; Ribi adjuvants (available from Ribi ImmunoChem Research, Inc., Hamilton, MT) ; and saponins and their derivatives, such as Quil A (available from Superfos Biosector A/S, Denmark) . Carriers are typically compounds that increase the half-life of a therapeutic composition in the treated animal. Suitable carriers include, but are not limited to, polymeric controlled release formulations, biodegradable implants, liposomes, bacteria, viruses, oils, esters, and glycols. One embodiment of the present invention is a controlled release formulation that is capable of slowly releasing a composition of the present invention into an animal. As used herein, a controlled release formulation comprises a composition of the present invention in a controlled release vehicle. Suitable controlled release vehicles include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, and transdermal delivery systems. Other controlled release formulations of the present invention include liquids that, upon administration to an animal, form a solid or a gel in situ . Preferred controlled release formulations are biodegradable (i.e., bioredible) . A preferred controlled release formulation of the present invention is capable of releasing a composition of the present invention into the blood of the treated animal at a constant rate sufficient to attain therapeutic dose levels of the composition to protect an animal from disease caused by parasitic helminths. The therapeutic composition is preferably released over a period of time ranging from about 1 to about 12 months. A controlled release formulation of the present invention is capable of effecting a treatment for preferably at least about 1 month, more preferably at least about 3 months and even more preferably for at least about 6 months, even more preferably for at least about 9 months, and even more preferably for at least about 12 months. In order to protect an animal from disease caused by a parasitic helminth of the present invention, a therapeutic composition of the present invention is administered to the animal in an effective manner such that the composition is capable of protecting that animal from a disease caused by a parasitic helminth. For example, an isolated protein or mimetope thereof, when administered to an animal in an effective manner, is able to elicit (i.e., stimulate) an immune response, preferably including both a humoral and cellular response, that is sufficient to protect the animal from the disease. Similarly, an antibody of the present invention, when administered to an animal in an effective manner, is administered in an amount so as to be present in the animal at a titer that is sufficient to protect the animal from the disease, at least temporarily. Oligonucleotide nucleic acid molecules of the present invention can also be administered in an effective manner, thereby reducing expression of filariid nematode CP proteins in order to interfere with development of parasitic helminths targeted in accordance with the present invention. Therapeutic compositions of the present invention can be administered to animals prior to infection in order to prevent infection and/or can be administered to animals after infection in order to treat disease caused by the parasitic helminth. For example, proteins, mimetopes thereof, and antibodies thereof can be used as immunotherapeutic agents. Acceptable protocols to administer therapeutic compositions in an effective manner include individual dose size, number of doses, frequency of dose administration, and mode of administration. Determination of such protocols can be accomplished by those skilled in the art. A suitable single dose is a dose that is capable of protecting an animal from disease when administered one or more times over a suitable time period. For example, a preferred single dose of a protein, mimetope or antibody therapeutic composition is from about 1 microgram (μg) to about 10 milligrams (mg) of the therapeutic composition per kilogram body weight of the animal. Booster vaccinations can be administered from about 2 weeks to several years after the original administration. Booster vaccinations preferably are administered when the immune response of the animal becomes insufficient to protect the animal from disease. A preferred administration schedule is one in which from about 10 μg to about 1 mg of the therapeutic composition per kg body weight of the animal is administered from about one to about two times over a time period of from about 2 weeks to about 12 months. Modes of administration can include, but are not limited to, subcutaneous, intradermal, intravenous, intranasal, oral, transdermal and intramuscular routes. According to one embodiment, a nucleic acid molecule of the present invention can be administered to an animal in a fashion to enable expression of that nucleic acid molecule into a protective protein or protective RNA (e.g., antisense RNA, ribozyme or RNA drug) in the animal to be protected from disease. Nucleic acid molecules can be delivered to an animal in a variety of methods including, but not limited to, (a) administering a naked (i.e., not packaged in a viral coat or cellular membrane) nucleic acid vaccine (e.g., as naked DNA or RNA molecules, such as is taught, for example in Wolff et al., 1990, Science 247, 1465-1468) or (b) administering a nucleic acid molecule packaged as a recombinant virus vaccine or as a recombinant cell vaccine (i.e., the nucleic acid molecule is delivered by a viral or cellular vehicle) . A naked nucleic acid vaccine of the present invention includes a nucleic acid molecule of the present invention and preferably includes a recombinant molecule of the present invention that preferably is replication, or otherwise amplification, competent. Such a vaccine can comprise any nucleic acid molecule or recombinant molecule of the present invention. Preferred naked nucleic acid vaccines include at least a portion of a viral genome (i.e., a viral vector). Preferred viral vectors include those based on alphaViruses, poxviruses, adenoviruses, herpesviruses, and retroviruses, with those based on alphaviruses (such as Sindbis or Semliki virus) , species-specific herpesviruses and species-specific poxviruses being particularly preferred. Any suitable transcription control sequence can be used, including those disclosed as suitable for protein production. Particularly preferred transcription control sequence include cytomegalovirus intermediate early (preferably in conjunction with Intron-A) , Rous Sarcoma Virus long terminal repeat, and tissue-specific transcription control sequences, as well as transcription control sequences endogenous to viral vectors if viral vectors are used. The incorporation of "strong" poly(A) sequences are also preferred. Naked nucleic acid vaccines of the present invention can be administered in a variety of ways, with intramuscular, subcutaneous, intradermal, transdermal, intranasal and oral routes of administration being preferred. A preferred single dose of a naked nucleic acid vaccine ranges from about 1 nanogram (ng) to about 100 μg, depending on the route of administration and/or method of delivery, as can be determined by those skilled in the art. Suitable delivery methods include, for example, by injection, as drops, aerosolized and/or topically. Suitable excipients include, for example, physiologically acceptable aqueous solutions (e.g., phosphate buffered saline as well as others disclosed above) , liposomes (including neutral or cationic liposomes) , and other lipid membrane-based vehicles (e.g., micelles or cellular membranes). A recombinant virus vaccine of the present invention includes a recombinant molecule of the present invention that is packaged in a viral coat and that can be expressed in an animal after administration. Preferably, the recombinant molecule is packaging-deficient. A number of recombinant viruses can be used, including, but not limited to, those based on alphaviruses, poxviruses, adenoviruses, herpesviruses, and retroviruses. Preferred recombinant virus vaccines are those based on alphaviruses (such as Sindbis virus) , species-specific herpesviruses and species-specific poxviruses. Methods to produce and use recombinant virus vaccines are disclosed in PCT Publication No. WO 94/17813, by Xiong et al., published August 18, 1994, which is incorporated by reference herein in its entirety. When administered to an animal, a recombinant virus vaccine of the present invention infects cells within the immunized animal and directs the production of a protective protein or RNA nucleic acid molecule that is capable of protecting the animal from disease caused by a parasitic helminths as disclosed herein. For example, a recombinant virus vaccine comprising a D. immitis CP nucleic acid molecule of the present invention is administered according to a protocol that results in the animal producing a sufficient immune response to protect itself from heartworm. A preferred single dose of a recombinant virus vaccine of the present invention is from about 1 x IO 4 to about 1 x IO 7 virus plaque forming units (pfu) per kilogram body weight of the animal. Administration protocols are similar to those described herein for protein-based vaccines, with subcutaneous, intramuscular, intranasal and oral administration routes being preferred. A recombinant cell vaccine of the present invention includes recombinant cells of the present invention that express at least one protein of the present invention. Preferred recombinant cells for this embodiment include Salmonella , E. coli , Listeria , Mycobacterium, S. frugiperda , BHK, CV-1, myoblast G8, COS (e.g., COS-7) , Vero, MDCK and CRFK recombinant cells. Recombinant cell vaccines of the present invention can be administered in a variety of ways but have the advantage that they can be administered orally, preferably at doses ranging from about IO 8 to about 10 12 cells per kilogram body weight. Administration protocols are similar to those described herein for protein-based vaccines. Recombinant cell vaccines can comprise whole cells or cell lysates. The efficacy of a therapeutic composition of the present invention to protect an animal from disease caused by a parasitic helminth can be tested in a variety of ways including, but not limited to, detection of protective antibodies (using, for example, proteins or mimetopes of the present invention) , detection of cellular immunity within the treated animal, or challenge of the treated animal with the parasitic helminth to determine whether the treated animal is resistant to disease. Such techniques are known to those skilled in the art. One preferred embodiment of the present invention is the use of filariid nematode CP proteins, nucleic acid molecules and antibodies of the present invention, and particularly 17. immitis CP proteins, nucleic acid molecules and antibodies of the present invention, to protect an animal from heartworm. Preferred therapeutic compositions are those that are able to inhibit at least one step in the portion of the parasite's development cycle that includes L3 larvae, third molt, L4 larvae, fourth molt and immature adult prior to entering the circulatory system. In dogs, this portion of the development cycle is about 70 days. Particularly preferred therapeutic compositions include 17. immitis- based therapeutic compositions of the present invention. Such compositions are administered to animals in a manner effective to protect the animals from heartworm. Additional protection may be obtained by administering additional protective compounds, including other 17. immitis proteins, nucleic acid molecules and antibodies. Another preferred embodiment of the present invention is the use of filariid nematode CP proteins, nucleic acid molecules and antibodies of the present invention, and particularly O. volvulus CP proteins, nucleic acid molecules and antibodies of the present invention, to protect a human from onchocerciasis. Preferred therapeutic compositions are those that are able to inhibit at least one step in the portion of the parasite's development cycle that includes L3 larvae, third molt, L4 larvae, fourth molt and immature adult prior to entering the subcutaneous tissues. In humans infected with O. volvulus, this portion of the development cycle is about 150 days. Particularly preferred therapeutic compositions include O. volvulus- based therapeutic compositions of the present invention. Such compositions are administered to humans in a manner effective to protect the treated humans from onchocerciasis. Additional protection may be obtained by administering additional protective compounds, including other Onchocerca , preferably O . volvulus , proteins, nucleic acid molecules and antibodies. An inhibitor of cysteine protease activity can be identified using parasitic helminth, and preferably 17. immitis and/or O . volvulus CP proteins of the present invention. One embodiment of the present invention is a method to identify a compound capable of inhibiting cysteine protease activity of a parasitic helminth. Such a method includes the steps of (a) contacting (e.g., combining, mixing) an isolated filariid nematode CP protein with a putative inhibitory compound under conditions in which, in the absence of the compound, the protein has cysteine protease activity, and (b) determining if the putative inhibitory compound inhibits the cysteine protease activity. . Putative inhibitory compounds to screen include organic molecules, antibodies (including mimetopes thereof) and substrate analogs. Methods to determine cysteine protease activity are known to those skilled in the art. It is also within the scope of the present invention to use isolated proteins, mimetopes, nucleic acid molecules and antibodies of the present invention as diagnostic reagents to detect infection by parasitic helminths. Such diagnostic reagents can be supplemented with additional compounds that can detect other phases of the parasite's life cycle. The following examples are provided for the purposes of illustration and are not intended to limit the scope of the present invention. EXAMPLES Example 1 This Example describes the cloning and sequencing of a filariid nematode cysteine protease nucleic acid molecule of the present invention. A 17. immitis cysteine protease nucleic acid molecule of about 1298 nucleotides, denoted nDiCP 1298 , was identified by its ability to encode a protein that selectively bound to at least one component of immune serum collected from a dog immunized with chemically abbreviated 17. immitiε larval infections in the following manner. A 17. immitiε cDNA expression library was constructed in Uni-ZAP™ XR vector (available from Stratagene Cloning Systems, La Jolla, CA) , using Stratagene's ZAP-cDNA Synthesis Kit protocol and third stage larval mRNAs. Using the protocol described in the Stratagene picoBlue immunoscreening kit, the L3 larval cDNA expression library was screened with immune dog sera. The production and use of immune dog serum to identify heartworm vaccine candidates is disclosed in PCT Publication No. WO 92/13560, published August 20, 1992. Immunoscreening of duplicate plaque lifts of the cDNA library with the same immune dog serum identified the nucleic acid molecule nDiCP 1298 . The plaque-purified clone including nDiCP 1298 was converted into a double- stranded plasmid using ExAssist™ helper phage and SOLR™ E. coli according to the in vivo excision protocol described in the Stratagene ZAP-cDNA Synthesis Kit. Double-stranded plasmid DNA was prepared using an alkaline lysis protocol, such as that described in Sambrook et al., ibid. The double-stranded plasmid containing the fragment is denoted herein as recombinant molecule p3gal-nDiCP 1298 . The plasmid DNA was digested with EcoRI and Xhol restriction endonucleases. The digestion released two 17. immitiε DNA fragments of about 450 and about 848 nucleotides from the nDiCP 1298 nucleic acid molecule. As described in more detail below, nucleic acid molecule nDiCP 1298 has been shown to encode a cysteine protease protein. Nucleic acid molecule nDiCP 1298 was sequenced using the Sanger dideoxy chain termination method, as described in Sambrook et al., ibid. An about 1298 nucleotide consensus sequence of the entire nDiCP 1298 nucleic acid molecule was determined and is denoted herein as SEQ ID NO:l. The nucleic acid sequence SEQ ID N0:1 includes an open reading frame spanning from about nucleotide 1 through about nucleotide 1194, with a first ATG codon spanning from about nucleotide 97 through about nucleotide 99 and a termination (stop) codon spanning from about nucleotide 1195 through about 1197. A putative polyadenylation signal (5' AATAAA 3') is located from about nucleotide 1265 through about nucleotide 1270. The amino terminus of the nucleic acid sequence represented by SEQ ID NO:l encodes a hydrophobic region as determined using a standard hydrophilicity plot. The open reading frame extending from the first nucleotide of nDiCP 1298 up to the stop codon is a nucleic acid molecule of about 1194 nucleotides, denoted herein as nDiCP 1194 , which encodes a protein of about 398 amino acids, denoted herein as PDiCP 398 , the deduced amino acid sequence of which is represented herein as SEQ ID NO:2. Assuming that the ATG located from about nucleotide 97 through about nucleotide 99 represents the initiation (start) codon, SEQ ID NO:l encodes a protein having an amino acid sequence of about 366 amino acids, denoted herein as PDiCP 366 . That open reading frame is denoted herein as nucleic acid molecule nDiCP 1098 and spans from about nucleotide 97 through about nucleotide 1194 of SEQ ID NO:i. Assuming that the ATG located from about nucleotide 127 through about nucleotide 129 represents the initiation codon, SEQ ID NO:l encodes a protein having an amino acid sequence of about 356 amino acids, denoted herein as PDiCP 356 . That open reading frame is denoted herein as nucleic acid molecule nDiCP 1068 and spans from about nucleotide 127 through about nucleotide 1194 of SEQ ID NO:l. Assuming that the ATG located from about nucleotide 253 through about nucleotide 255 represents the initiation codon, SEQ ID NO:l encodes a protein having an amino acid sequence of about 314 amino acids, denoted herein as PDiCP 314 . That open reading frame is denoted herein as nucleic acid molecule nDiCP 942 and spans from about nucleotide 253 through about nucleotide 1194 of SEQ ID NO:l. The very highly conserved catalytic residues of members of the papain family of cysteine peptidases are a cysteine at amino acid position 25 (C25) and a histidine residue at position 159 (H159) of the mature, processed peptide. Other amino acid residues important for catalysis include a glutamine at position 19 (Q19) and asparagine at position 175 (N175) . The numbering of these amino acids correspond to the amino acid position of the mature papain sequence (Genbank Ace. No. M15203) . Based on a homology alignment of the PDiCP 356 deduced amino acid sequence with known papain amino acid sequences, the predicted mature protein resulting from the processing of the PDiCP 356 sequence, referred to as PDiCP 213 (SEQ ID NO:21), would begin with the leucine at residue 144 of PDiCP 356 . PDiCP 213 also contains the papain family conserved residues believed to be involved in catalysis, namely, a cysteine at residue 25 (C25) , a histidine at residue 160 which corresponds to the H159 of papain, a glutamine at position 19 (Q19) and an asparagine at residue 181 which corresponds to the N175 of papain. In addition, many members of the papain Cl family contain a proline residue at position 2 of the mature, processed enzyme. The PDiCP 213 amino acid sequence has a proline at position 2 of the predicted mature enzyme. To confirm the 1. immitiε origin of the isolated L3 cysteine protease cDNA nucleic acid molecules, a Southern blot containing about 10 micrograms of EcoRI restricted D. immitis genomic DNA and Aedes aegypti genomic DNA was hybridized under stringent conditions with p / 3gal-nDiCP 1298 DNA radiolabeled by random priming with the Megaprime DNA Labeling System (available from Amersham Life Science, Arlington Heights, IL) . The probe detected two bands of about 2500 and 700 nucleotides only in the 17. immitiε genomic DNA. A homology search of the non-redundant protein sequence database was performed through the National Center for Biotechnology Information using the BLAST network. This database includes + SwissProt + PIR + SPUpdate + GenPept + GPUpdate. SEQ ID NO:2 was found to have significant homology to certain cysteine proteases starting at about amino acid 85 of SEQ ID NO:2, corresponding to an ATG codon in SEQ ID NO:l spanning from about nucleotide 253 through about nucleotide 255. While not being bound by theory, this comparison suggests that the mature 17. immitiε cysteine protease is a protein of about 314 amino acids, denoted herein as PDiCP 314 , which has the deduced amino acid sequence represented herein as SEQ ID NO:4. PDiCP 314 is encoded by a nucleic acid molecule of about 942 nucleotides, denoted herein as nDiCP 942 , the nucleic acid sequence of which is represented herein as SEQ ID NO:3, which corresponds to a region spanning from about nucleotide 253 through about nucleotide 1194 of SEQ ID N0:1. Based on SEQ ID NO:4, PDiCP 314 has a calculated molecular weight of about 36.2 kD and an estimated pi of about 9.36. SEQ ID NO:4 was found to be about 37% identical to Norway lobster cathepsin L (Genbank Ace. No. S47433) ; about 30% identical to Dictyostelium discoideum cysteine proteinase 2 (Ace. No. X03344) ; about 39% identical to Sarcophoga peregrina pro-cathepsin (Ace. No. LD16533) ; about 36% identical to Faεciola hepatica cathepsin L-like proteinases (Ace. No. S43991) ; about 35% identical to Faεciola hepatica cathepsin (Ace. No. L33772) ; about 36% identical to Schiεtoεoma manεoni cathepsin L (Ace. No. S44151) : about 36% identical to Faεciola hepatica cathepsin L-like protease (Ace. No. Z22765) ; about 30% identical to Trichomonas vaginalis putative cysteine proteinase (Ace. No. X77221) ; about 35% identical to Entamoeba histolytica cysteine proteinase (Ace. No. A23705) ; and about 28% identical to Tricj-ojnonas vaginaliε cysteine proteinase (Ace. No. S41427) . The corresponding region of SEQ ID NO:4 is also about 23% identical to the deduced amino acid sequence of the D. immitiε amplified genomic PCR fragment nDiCP 143 disclosed in PCT Patent Publication No. WO 95/32988, published December 7, 1995, which is incorporated by reference herein in its entirety. The nucleic acid sequence represented by SEQ ID NO:l was found to be about 48.4% identical to C. papaya mRNA for chymopapain (Genbank Ace. No. X97789) ; about 44.7% identical to Faεciola hepatica cathepsin L-like proteinase (Genbank Ace. No. L33771) ; and about 42.2% identical to Schistosoma mansoni mRNA for cathepsin L (Genbank Ace. No. Z32529) . Example 2 This example discloses the production of a recombinant cell of the present invention. Recombinant molecule pHis-nDiCP 945 , containing 17. immitis L3 cysteine protease nucleic acid molecule nDiCP 945 operatively linked to trc transcription control sequences and to a fusion sequence encoding a poly-histidine segment comprising 6 histidines, was produced in the following manner. An about 945 nucleotide DNA fragment containing nucleotides spanning from about nucleotide 253 through about nucleotide 1197 of SEQ ID NO:l, called nDiCP 945 , was polymerase chain reaction (PCR) amplified from recombinant molecule p / 9gal-nDiCP 1298 , described in Example 1, using the following primers: primers CP sen 5' AACGGTGAGGATCCAGCGATGAAAAAATTAGAAAC 3' (SEQ ID NO:8) (BamHI site in bold) and CP ant 5' ATTAAAAGATCTTTATATGGGGAATGAAGCCATCG 3' (SEQ ID NO:9) (Bglll site in bold) . The PCR product was digested with BamHI and Bglll restriction endonucleases, gel purified and subcloned into expression vector pTrcHisB (available from Invitrogen, San Diego, CA) that had been digested with BamHI. The resulting recombinant molecule pHis-nDiCP 945 was transformed into E. coli to form recombinant cell E. coli:pHis-nDiCP 945 . Example 3 This Example describes the production in bacteria of a filariid nematode cysteine protease protein of the present invention. This Example also discloses an antibody preparation produced in response to the parasitic helminth protein. Recombinant cell E. coli:pHis-nDiCP 945 , produced as described in Example 2, was cultured in shake flasks containing an enriched bacterial growth medium containing 0.1 mg/ml ampicillin and 0.1% glucose at about 32"C. When the cells reached an OD 600 of about 0.4, expression of 17. immitis nDiCP 945 was induced by addition of about 0.5 mM isopropyl-/9-D-thiogalactoside (IPTG), and the cells cultured for about 3 hours at about 32*C. Protein production was monitored by SDS PAGE of recombinant cell lysates, followed by Coomassie blue staining, using standard techniques. Recombinant cell E. coli:pHis-nDiCP 945 produced a fusion protein, denoted herein as PHIS-PDiCP 314 , that migrated with an apparent molecular weight of about 37 kD. Immunoblot analysis of recombinant cell E. coli:pHis-nDiCP 945 lysates indicated that the about 37 kD protein was able to bind to a T7 tag monoclonal antibody (available from Novagen, Inc., Madison, WI) directed against the fusion portion of the recombinant PHIS-PDiCP 314 fusion protein. The PHIS-PDiCP 314 histidine fusion peptide was separated from E. coli proteins by nickel chelation chromatography and an imidazole gradient. Immunoblot analysis of the total E. coli:pHis-nDiCP 945 lysate, column eluate and column void volume using the T7 tag monoclonal antibody indicated that the PHIS-PDiCP 314 37 kD protein bound to the nickel column and was eluted using an imidazole gradient. A rabbit was immunized twice with PHIS-PDiCP 314 that had been purified by chelation chromatography. Antisera collected from this rabbit was denoted anti-PHIS-PDiCP 314 antisera. Immunoblot analysis of E. coli:pHis-nDiCP 945 lysates indicated that the anti-PHIS-PDiCP 314 antisera selectively bound to the PHIS-PDiCP 314 37 kD protein produced by the recombinant cell. Example 4 This Example describes the production of a 17. immitis L3 cysteine protease protein of the present invention in a eukaryotic cell. . Recombinant molecule pVL1393-nCP 945 , containing a 17. immitis L3 cysteine protease nucleic acid molecule operatively linked to baculovirus polyhedron transcription control sequences was produced in the following manner. An about 945 nucleotide DNA fragment containing nucleotides spanning from about nucleotide 253 through about nucleotide 1197 of SEQ ID NO:l, called nDiCP 945 , was PCR amplified from recombinant molecule pj9gal-nDiCP 1298 , described in Example 1, using the following primers: a sense primer BvCP sen (5' CGCGGATCCTATAAATATGAAAAAATTAGAAACC 3' (SEQ ID NO:10) and an antisense primer BvCP ant 5* CGCGGATCCTTATATGGGGAATGAAGC 3' (SEQ ID NO:11), which have BamHI sites (in bold) incorporated into the primers. The N-terminal primer was designed from the nucleic acid sequence of nDiCP 1298 with modifications to enhance expression in the baculovirus system. The PCR product was digested with BamHI restriction endonuclease, gel purified and subcloned into baculovirus shuttle plasmid pVL1393 (available from Invitrogen Inc. , San Diego, CA) that had been cleaved with BamHI. The resulting recombinant molecule, denoted herein as pVL1393-nDiCP 945 was co-transfected into S. frugiperda Sf9 cells (donated by the Colorado Bioprocessing Center, Fort Collins, CO) with linear wild type baculovirus DNA (AcMNPV) and insectin cationic liposomes (available from Invitrogen) to form: 5. frugiperda:pVL1393-nDiCP 945 . The proper orientation of the pVL1393-nDiCP 945 insert was verified by restriction enzyme mapping. The resulting recombinant virus, denoted vBV-nDiCP 945 , was cultivated for increased production of recombinant virus and expression of PDiCP 314 was verified by immunoblot blot analysis. Immunoblot analysis using rabbit anti-PHIS-PDiCP 314 antisera (described in Example 3) demonstrated that insect cells infected with recombinant baculovirus vBV-nDiCP 945 expressed a protein detected in the culture lysates. This protein encoded by nDiCP 945 , namely PDiCP 314 , migrated with an apparent molecular weight of about 35 kD. Sf9 cells infected with wild type baculovirus did not express this 35 kD protein. Example 5 This Example demonstrates the use of a 17. immitis L3 cysteine protease nucleic acid molecule of the present invention to obtain a nucleic acid molecule of another filariid nematode. A. nOVCP 291 O . volvulus L3 cysteine protease nucleic acid molecule nOvCP 291 was obtained in the following manner. £>. immitis L3 cysteine protease nucleic acid molecule nDiCP 1298 , produced as described in Example 1, was cleaved with .EcoRI and Xhol to produce two fragments of about 850 bp and 450 bp that were gel purified and mixed hexamer labeled with Amersham's Megaprime DNA Labeling System (available from Amersham Corp., Arlington Heights, IL) . These labeled fragments (i.e., nDiCP 8S0 and nDiCP 450 ) were used to screen an O. volvulus L3 cDNA library for plaques having nucleic acid molecules that could form stable hybrids with the 17. immitis nucleic acid molecules under stringent hybridization conditions. Approximately 70,000 plaques from an O. volvuluε L3 cDNA library were screened with the mixed hexamer labeled 17. immitiε heterologous probe using standard hybridization techniques as described by Sambrook et al., ibid. Numerous positive signals were identified from this primary hybridization screen. These regions were plugged, and the phage pools were screened further by plaque hybridization screening using the same mixed hexamer labeled D. immitiε nDiCP 1298 fragment probe. One L3 cDNA clone was plaque purified, excised, and subcloned into pBluescript (available from Stratagene) . Plasmid DNA was analyzed by EcoRI restriction digestion and found to contain an insert of about 290 nucleotides. The insert of the plasmid was sequenced as described in Example 1 and determined to have about a 291- nucleotide nucleic acid sequence, represented herein as SEQ ID NO:5. A nucleic acid molecule consisting of SEQ ID NO:5 is referred to herein as nOvCP 291 . Translation of SEQ ID NO:5 indicated that nθvCP 291 includes an open reading frame spanning from about nucleotide 2 through about nucleotide 217 with a stop codon nucleotides spanning from about nucleotide 218 through about nucleotide 220, followed by a 3' untranslated region spanning from about nucleotide 221 through about nucleotide 291. The open reading frame encodes a protein of about 72 amino acids, referred to herein as POvCP^, the amino acid sequence of which is represented herein as SEQ ID NO:6. Nucleic acid molecule nθvCP 216 consists of the coding region of POvCP^, the nucleic acid sequence of which is represented herein as SEQ ID NO:7. Comparison of the O. volvulus POvCP^ amino acid sequence with the corresponding amino acid sequence of 17. immitis PDiCP 398 indicate that the two sequences share about 67% identity. About 77% identity was found between the amino acid sequence encoded by approximately 284 nucleotides of the coding region plus the proposed 3' untranslated region of the O. volvulus nOvCP 291 and the amino acid sequence of the 3' end of D. immitis nDiCP 1298 . Comparison of the amino acid sequence of the coding region of O. volvulus nOvCP 216 and the corresponding region of 17. immitis nDiCP 1298 indicate that the two regions share about 80% identity. About 65% identity was found between about 66 amino acids of O. volvulus POvCP 72 and the amino acid sequence of the 3' end of cathepsin L-like proteinase from liver fluke, Faεciola hepatica . About 65% identity was found between about 62 amino acids of O. volvuluε POvCP^ and the amino acid sequence of the 3' end of cathepsin L proteinase from parasitic trematode, Schiεtoεoma mansoni . About 63% identity was found between approximately 65 amino acids of O . volvulus POvCP^ and the amino acid sequence of the 3' end of chick cathepsin L (EC 3.4.22.15) . B. nOvCP 1306 An O. volvulus cysteine protease nucleic acid molecule, referred to herein as nOvCP 1306 , was produced by PCR amplification using the following method. Antisense primer ovcpa-1, having nucleic acid sequence 5' CAT GTT CCC CTT ATT TC 3' (represented herein as SEQ ID NO:12) was used in combination with the sense vector primer T3X, having nucleic acid sequence 5' CAT GTT CCC CTT ATT TC 3' (represented herein as SEQ ID NO:13), to PCR amplify, using standard techniques, a DNA fragment from an O. volvulus L3 cDNA library (Lambda Uni-ZAP XR, reference number SAW94WL-OvL3) constructed by S. Williams and W. Lu (Smith College, Northampton, MA) . A resulting PCR product of about 1272 bp, referred to herein as nOvCP 1272 , was gel purified and cloned into the pCRII Vector ® System (obtained from Invitrogen) , and subjected to standard DNA sequencing techniques. A composite nucleic acid sequence including an O. volvuluε cysteine protease apparent full-length coding region, referred to herein as nOvCP 13fJ6 , was deduced using the nucleic acid sequence of nOvCP 291 and nOvCP 1272 , and is denoted herein as SEQ ID NO:14. The nucleic acid sequence SEQ ID NO:14 includes an open reading frame spanning from about nucleotide 20 through about nucleotide 1222, with a first ATG codon spanning from about nucleotide 20 through about nucleotide 22 and a termination (stop) codon spanning from about nucleotide. 1223 through about nucleotide 1225. SEQ ID NO:14 also encodes a putative hydrophobic signal peptide of about 23 amino acids, the coding sequence spanning from about nucleotide 20 through about nucleotide 88. Translation of SEQ ID NO:14 indicates that SEQ ID NO:14 encodes a protein of about 408 amino acids, denoted herein as POvCP 408 , having the deduced amino acid sequence represented herein as SEQ ID NO:15. The open reading frame extending from nucleotide 20 of nOvCP 1306 up to the stop codon is a nucleic acid molecule of about 1203 nucleotides, denoted herein as nθvCP 1203 and represented by SEQ ID NO:16, which encodes a protein of about 401 amino acids, denoted herein as POvCP 401 , having the deduced amino acid sequence represented herein as SEQ ID NO:31. Based on SEQ ID NO:31, POvCP 401 has a calculated molecular weight of about 45.8 kD and an estimated pi of about 9.4. Comparison of the O. volvuluε POvCP 401 amino acid sequence with the corresponding amino acid sequence of 17. immitis PDiCP 398 indicate that the two sequences share about 49% identity. Comparison of the O. volvuluε nOvCP 1306 nucleic acid sequence with the corresponding nucleic acid sequence of 17. immitis nDiCP 1298 indicate that the two sequences share about 71% identity. Analysis of the amino acid sequence of POvCP 401 indicated significant conservation of residues involved in proteolytic processing of the pre-protein to form a processed pro-protein. A BLAST homology search indicated that about 330 amino acids of POvCP 401 was most similar in amino acid sequence to the amino acid sequence of a rabbit cathepsin K precursor (OC-2 protein, Genbank Ace. No. P43236) , there being about 44% identity between the two regions. A BLAST homology search indicated that about 1005 nucleotides of the O. volvuluε nθvCP 1306 nucleic acid sequence was most similar in nucleic acid sequence to the nucleic acid sequence of a Spirometra manεonoides cysteine protease (Genbank Ace. No. U51913) , there being about 51% identity between the two regions. Taken together, these examples clearly indicate that knowledge of the nucleic acid sequence of 17. immitiε and O. volvulus cysteine protease nucleic acid molecules of the present invention enables the identification and isolation of additional filariid nematode nucleic acid molecules of the present invention. Example 7 This Example describes the production of a eukaryotic recombinant cell and use of that cell to produce a eukaryotic version of a 17. immitis L3 cysteine protease protein of the present invention. Recombinant molecule pKB3poly-nDiCP 1071 , containing a 17. immitis L3 cysteine protease nucleic acid molecule spanning nucleotides from about 127 through about 1197 of SEQ ID NO:l operatively linked to the vaccinia virus pll late promoter transcription control sequences was produced in the following manner. The pKB3poly poxvirus shuttle vector was created by modifying a region of plasmid pKB3 (P^-type) (pKB3 (P^-type) plasmid (described in U.S. Patent No. 5,348,741, by Esposito et al., issued September 20, 1994) such that the initiation codon linked to the pll promoter was mutated and additional unique polylinker restriction sites were added. The resulting poxvirus vector, referred to as pKB3poly, requires the insert DNA to provide the. ATG initiation codon when inserted downstream of the pll promoter. The pKB3poly vector is designed such that foreign DNA cloned into the polylinker region of pKB3poly vector will recombine into the thymidine kinase (TK) gene of wildtype poxvirus. In order to subclone a 17. immitis L3 cysteine protease nucleic acid molecule into the pKB3poly expression vector, an about 1071 nucleotide 17. immitis L3 cysteine protease nucleic acid molecule-containing fragment spanning from about nucleotide 127 through about nucleotide 1197 of SEQ ID NO:l, called nDiCP 107l , was PCR amplified from recombinant molecule pβgal-nDiCP 1298 , described in Example 1, using the following primers: a sense primer EukCP sen 5' CGGGGTACCAGGAAATATGACGAGACTTAC 3' (SEQ ID NO:17) and an antisense primer EukCP ant 5* CGGGGTACCTTATATGGGGAATGAAGC 3' (SEQ ID NO:18), which have Asp718I sites (in bold) incorporated into the primers. The PCR product was digested with Asp718I restriction endonuclease, gel purified and subcloned into the pKB3poly shuttle vector which had been digested with Asp718I restriction endonuclease, treated with calf intestinal phosphatase and gel purified to produce recombinant molecule pKB3poly-nDiCP 1071 . The proper orientation of the insert was verified by restriction digest mapping. In order to produce a recombinant raccoon poxvirus capable of directing the production of PDiCP 356 , BS-C-1 African green monkey kidney cells (obtained from American Type Culture Collection (ATCC) , Rockville, MD) were infected with wild type raccoon poxvirus RCN CDC/V71-I- 85A) (obtained from Dr. Joseph Esposito; Esposito et al, 1985, Virology 143,230-251) and then transfected with the pKB3poly-nDiCP 1071 vector DNA by calcium phosphate precipitation to form recombinant cell BSCl:pKB3poly- nDiCP 1Q71 . The resulting recombinant virus, denoted Rcn- nDiCP 1071 , was plaque purified twice in RAT-2 rat embryo, thymidine kinase mutant cells (available from ATCC) in the presence of bromodeoxyuridine (BUDR) to select for TK " recombinants. The TK " recombinant virus was plaque purified once and then cultivated in BS-C-l cells without BUDR. Expression of the 17. immitis L3 cysteine protease recombinant protein was monitored by SDS PAGE of infected BS-C-l cell lysates, followed by immunoblot analysis with the rabbit anti-PHIS-PDiCP 314 antisera (described in Example 3) . Recombinant cell BSC1:pKB3poly-nDiCP 1071 produced a eukaryotic version of PDiCP 356 , that migrated with an apparent molecular weight of about 42 kD and that . was selectively bound by rabbit anti-PHIS-PDiCP 314 antisera. Example 8 This Example describes the production of a eukaryotic recombinant cell and use of that cell to produce a multivalent virus vaccine capable of expressing both D. immitis L3 cysteine protease and 17. immitis PLA2 proteins (17. immitis PLA2 nucleic acid molecules and proteins are described in PCT International Publication No. WO 94/15593, published July 21, 1994). Recombinant molecule pll-nDiCP 1071 /pSyn-nDiPLA2 453 , containing two 17. immitis nucleic acid molecules operatively linked to separate promoters was produced in the following manner. pll/pSyn pox virus shuttle vector was created by modifying a region of plasmid pKB3poly shuttle plasmid (described in Example 7) in the following manner. A double stranded linker molecule was synthesized to contain the poxvirus promoter pSyn (see, for example, Davison et al, 1990, iVuc. Acids Res . 18 , 4285-4286) as follows. Two complimentary oligonucleotides, EJH016 and EJH017 were synthesized and have the following nucleotide sequence: EJH016 5' GATCCAATTGGATCAGCTTTTTTTTTTTTTTTTTTGG CATATAAATAAG 3 * (SEQ ID NO:19) with the BamHI cohesive end indicated in bold; and EJH017 5' GTACCTTATTTATATGCC AAAAAAAAAAAAAAAAAAGCTGATCCAATTG 3' (SEQ ID NO: 20) with the Asp718I cohesive end indicated in bold. The two oligonucleotides were annealed to create a 45 nucleotide double stranded region with a 4-nucleotide single stranded BamHI cohesive terminus on one end and a 4- nucleotide single stranded Asp718I cohesive terminus on the other end to facilitate directional cloning of this fragment into the unique BamHI and Asp718I sites of pKB3poly shuttle plasmid. The resulting poxvirus vector, referred to as pll/pSyn, requires the insert DNA to provide the ATG initiation codon when inserted downstream of the pSyn or the P„ promoter. The pll/pSyn vector is designed such that foreign DNA cloned into the polylinker region of pll/pSyn vector will recombine into the TK gene of wildtype poxvirus. A recombinant molecule containing (a) a 17. immitiε PLA2 nucleic acid molecule containing the PLA2 open reading frame (described in WO 94/15593, iJid.), operatively linked to pSyn transcription control sequences and (b) a 17. immitiε L3 cysteine protease nucleic acid molecule spanning nucleotides from about 127 through about 1197 of SEQ ID NO: 1 operatively linked to the vaccinia virus P^ late promoter transcription control sequences was produced in the following manner. In order to subclone a PLA2 nucleic acid molecule into pll/pSyn expression vector, a nucleic acid molecule containing the PLA2 open reading frame was cleaved from 17. immitiε PLA2-nucleic acid molecule-containing vector p76-52.H3 (produced as described in Example 15 of WO 94/15593, ibid. ) using BamHI restriction endonuclease. The about 453 nucleotide insert DNA (referred to as Rcn- nDiPLA2 453 ) was treated with Klenow enzyme to create blunt ends resulting in the production of nucleic acid molecule nRcnDiPLA2 453 , gel purified and subcloned into the pll/pSyn shuttle vector, which had been restricted with Asp718I and EcoRI restriction endonuclease, treated with Klenow enzyme to create blunt ends, treated with calf intestinal phosphatase and gel purified, to produce recombinant molecule pll/pSyn-nDiPLA2 453 . The proper orientation of the Rcn-nDiPLA2 453 insert was verified by restriction digest mapping. In order to subclone a 17. immitiε L3 cysteine protease nucleic acid molecule into pll/pSyn-nDiPLA2 453 expression vector, a L3 cysteine protease nucleic acid molecule-containing fragment was cleaved from 17. immitiε pKB3poly-nDiCP l071 DNA (produced as in Example 7) , by Asp718I restriction endonuclease. The about 1071 nucleotide insert DNA (referred to as Rcn-nDiCP 1071 ) was treated with Klenow enzyme to create blunt ends resulting in the production of nucleic acid molecule nRcnDiCP l071 , gel purified and subcloned into the pll/pSyn-nDiPLA2 453 shuttle vector, which had been digested with Smal restriction endonuclease, treated with calf intestinal phosphatase and gel purified, to produce recombinant molecule pll-nDiCP 1071 /pSyn-nDiPLA2 453 . The proper orientation of the Rcn-nDiCP 1071 insert was verified by restriction digest mapping. In order to produce a recombinant raccoon poxvirus capable of directing the production of PDiCP 356 and PDiPLA2 150 , BS-C-l African green monkey kidney cells (obtained from ATCC, Rockville, MD) were infected with wild type raccoon poxvirus RCN CDC/V71-1-85A and then transfected with the pll-nDiCP 1rj71 /pSyn-nDiPLA2 453 vector DNA to form recombinant cell BSCl:pll-nDiCP 1071 /pSyn- nDiPLA2 453 . The resulting recombinant virus, denoted Rcn- nDiCP 107l -nDiPLA2 453 , was cultivated in RAT-2 rat embryo, thymidine kinase mutant cells as described in Example 7. Expression of the cysteine protease and the PLA2 recombinant proteins was monitored by SDS PAGE of infected BS-C-l cell lysates, followed by immunoblot analysis with the rabbit anti-PHIS-PDiCP 314 antisera and rabbit anti-PHIS-PDiPLA2 antisera (produced as described in Example 14 of WO 94/15593, ibid. ) . Example 9 This Example describes the production of a 17. immitiε L3 cysteine protease protein using a eukaryotic cell transformed with a 1. immitis L3 cysteine protease nucleic acid molecule of the present invention. Recombinant molecule pCMV-nDiCP l071 , containing a 17. immitiε L3 cysteine protease nucleic acid molecule spanning nucleotides from about 127 through about 1197 of SEQ ID NO:l operatively linked to the cytomegalovirus (CMV) promoter transcription control was produced in the following manner. The pCMV expression vector was produced as follows. Vector pRc/RSV (available from InVitrogen) was cleaved by restriction enzyme PvuII, and the 2963-base pair PvuII fragment gel purified. That fragment was self-ligated to form vector pRc/RSV(Pvu) , which contains a Rous Sarcoma Virus (RSV) long terminal repeat, a multiple cloning site, a bovine growth hormone polyadenylation sequence, a bacterial origin of replication and an ampicillin resistance gene. Expression vector PVXRC was produced by introducing a Hindlll fragment containing the cytomegalovirus (CMV) intermediate early promoter and first intron (i.e., Intron A) into pRc/RSV(Pvu) that had been cleaved by Hindlll. Expression vector pCMV was produced by introducing a Hindlll/Sspl fragment containing the CMV intermediate early promoter and first intron (i.e., Intron A) into pRc/RSV(Pvu) that had been cleaved by Hindlll and Nrul . In order to subclone a 17. immitiε L3 cysteine protease nucleic acid molecule into the pCMV expression vector, 17. immitiε L3 cysteine protease nucleic acid molecule-containing fragments were PCR amplified as described in Example 7. The about 1071 PCR product (referred to as nDiCP l071 ) was digested with Asp718I restriction endonuclease, gel purified and subcloned into the pCMV expression vector which had been restricted with Asp718I restriction endonuclease, treated with calf intestinal phosphatase and gel purified to produce recombinant molecule pCMV-nDiCP 1071 . The proper orientation of the insert was verified by restriction mapping. To produce the recombinant cell line BHK:pCMV- nDiCP 1rj71 , pCMV-nDiCP l071 was transfected into Baby Hamster Kidney Cells (BHK) (obtained from ATCC, Rockville, MD) was performed by standard procedures. Briefly, six-well polystyrene tissue culture plates were seeded with about 3 x 10 5 cells/well in 2 mis of MEM NEAA Earle' s salts (available from Irvine Scientific, Santa Ana CA) with 100 mM L-glutamine, 5% FBS (complete growth media) . Cells were grown to 80% confluence (about 48 hr) . The recombinant molecules to be transfected were purified using Qiagen tips (available from Qiagen Inc. , Chatsworth, CA) per manufacturer' s instructions. Using polystyrene plates, about 2 μg of each recombinant molecule was mixed with about 100 μl OptiMEM (available from Gibco BRL) . About 15 μl Lipofecta ine (available from Gibco BRL) was mixed with about 100 μl OptiMEM. The Lipofectamine mixture was then added to the recombinant molecule mixture and incubated at room temperature for about 30 min. After incubation, about 800 μl OptiMEM was added and the entire mixture overlaid onto the BHK cells that had been rinsed with OptiMEM. Cells were incubated at 37°C, 5% C0 2 , 90% relative humidity. The transfection mixture was then removed and replaced with about 2 mis complete growth media. Transfected cells were incubated at 37 β C, 5% C0 2 , 90% relative humidity for about 24 hr and harvested. The media was removed, the cells washed twice with about 2 mis PBS and scraped off the plate in about 1.5 ml PBS. The cells were pelleted by centrifugation, the PBS removed and the cells frozen. Expression of the D. immitis L3 cysteine protease recombinant protein was monitored by SDS PAGE of infected BHK cell lysates, followed by immunoblot analysis with the rabbit anti-PHIS-PDiCP 314 antisera. Recombinant cell BHK:pCMV-nDiCP 1071 produced a eukaryotic version of PDiCP 356 , that migrated with an apparent molecular weight of about 42 kD, that was bound selectively by rabbit anti-PHIS-PDiCP 314 antisera. Example 10 This Example describes the expression of 17. immitiε L3 cysteine proteasa native protein in different developmental stages of the 17. immitiε life cycle. Total protein was prepared from 0 hour third stage larvae (0-hr L3) , 48 hour third stage larvae (48-hr L3), 6 day fourth stage larvae (6-day L4) , and adult male or adult female worms. Immunoblot analysis of these antigen preparations with rabbit anti-PHIS-PDiCP 314 antiserum (produced as described in Example 3) indicated that the 17. immitis native cysteine protease protein migrated at about 22 kD and was detected only in the 48-hr L3 and 6- day L4 larval preparations. This 22 kD size of the 17. immitiε native protein is consistent with the predicted size of a mature protein resulting from processing of the amino acid sequence represented by PDiCP 356 . Cleavage of an amino terminal propeptide sequence to form an active enzyme is characteristic of peptidases of the papain family. The deduced amino acid sequences represented by nDiCP 1071 (described in Example 7) contains conserved amino acid residues present in the propeptide sequences, namely the ERFNN motif including glutamine (E) at position 64, arginine (R) at position 68, phenylalanine (F) at position 72, asparagine (N) at position 75 and asparagine (N) at position 83. Example 11 This example discloses the production of a recombinant cell of the present invention. Recombinant molecule pHis-nOvCP 1203 was produced in the following manner. An about 1203 nucleotide DNA fragment containing nucleotides spanning from about nucleotide 89 through about nucleotide 1222 of SEQ ID NO:14, called nOvCP 1203 , was polymerase chain reaction (PCR) amplified from nθvCP 1306 , described in Example 5, using the following primers: primers EXPCP5' 5' ACTGGATCCGCAAGTGCAACAGCTACGAGAAG 3' (SEQ ID NO:22) (BamHI site in bold) and EXPCP3' 5' TAAGGTACCTTATATGGGTATTGAAGCCAACGTTGCGATGTGGCACATGTTCCCCTT ATTTCG 3' (SEQ ID NO:23) (Kpnl site in bold). The PCR product was digested with BamHI restriction endonuclease, gel purified and subcloned into expression vector lambdaP R /Tori/S10HIS-RSET-A9 (produced as described in Example 7 of PCT Publication No. WO 95/24198, published September 14, 1995) that had been digested with BamHI and Kpnl . The resulting recombinant molecule pHis-nOvCP 1203 was transformed into E. coli to form recombinant cell E. coli :pHis-nθvCP 1203 . Example 12 This Example describes the production in bacteria of an O. volvulus L3 cysteine protease protein of the present invention. Recombinant cell . coli;pHis-nOvCP 1203 was produced as described in Example 11, was cultured in shake flasks containing an enriched bacterial growth medium containing 0.1 mg/ml ampicillin and 0.1% glucose at about 32 β C. When the cells reached an OD 600 of about 0.4, expression of O. volvuluε nθvCP 1203 was induced by addition of about 0.5 mM isopropyl-/3-D-thiogalactoside (IPTG), and the cells cultured for about 3 hours at about 32"C. Immunoblot analysis of recombinant cell E. coli:pHis-nOvCP 1203 lysates indicated that an about 47 kD protein was able to bind to a T7 tag monoclonal antibody (available from Novagen, Inc., Madison, WI) directed against the fusion portion of the recombinant pHIS-POvCP 401 fusion protein. SEQUENCE LISTING The following Sequence Listing is submitted pursuant to 37 CFR §1.821. A copy in computer readable form is also submitted herewith. Applicants assert pursuant to 37 CFR §1.821(f) that the content of the paper and computer readable copies of SEQ ID NO:l through SEQ ID NO:31 submitted herewith are the same. (1) GENERAL INFORMATION: (i) APPLICANT: Tripp, Cynthia A. Wisnewski, Nancy (ii) TITLE OF INVENTION: NOVEL FILARIID NEMATODE CYSTEINE PROTEASE PROTEINS, NUCLEIC ACID MOLECULES AND USES THEREOF (iii) NUMBER OF SEQUENCES: 31 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Sheridan Ross & Mclntosh (B) STREET: 1700 Lincoln Street, Suite 3500 (C) CITY: Denver (D) STATE: Colorado (E) COUNTRY: U.S.A. (F) ZIP: 80203 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/486,036 (B) FILING DATE: 07-JUN-1995 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Connell, Gary J. (B) REGISTRATION NUMBER: 32,020 (C) REFERENCE/DOCKET NUMBER: 2618-33-PCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (303) 863-9700 (B) TELEFAX: (303) 863-0223 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1298 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1194 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CTT CGA TTC ATT GCT TTA TTG GCC ATA CTC ACT TTC TTG ATC GAC TTT 48 Leu Arg Phe He Ala Leu Leu Ala He Leu Thr Phe Leu He Asp Phe 1 5 10 15 ACC GTC TCA TTC AAT GAT GAA ATT CTA CAG CTG AAA GAA GTA TTG GGA 96 Thr Val Ser Phe Asn Asp Glu He Leu Gin Leu Lys Glu Val Leu Gly 20 25 30 ATG TTT GAT GAA GAT TAC AGA TTA GGA AAT ATG ACG AGA CTT ACG TTT 144 Met Phe Asp Glu Asp Tyr Arg Leu Gly Asn Met Thr Arg Leu Thr Phe 35 40 45 GAT TTT CAA AAC GCT TTG AAA GAT TAC GGC GAT GGA GAA AAC AGT TAT 192 Asp Phe Gin Asn Ala Leu Lys Asp Tyr Gly Asp Gly Glu Asn Ser Tyr 50 55 60 AAA CTA ACT GCT GTG CAA TCT TTC CTC AAA AAA TTA GAA GAA AAC GGT 240 Lys Leu Thr Ala Val Gin Ser Phe Leu Lys Lys Leu Glu Glu Asn Gly 65 70 75 80 GAG GAA CAA GCG ATG AAA AAA TTA GAA ACC GAA TGG CAA GAG TAT TTA 288 Glu Glu Gin Ala Met Lys Lys Leu Glu Thr Glu Trp Gin Glu Tyr Leu 85 90 95 ACA GCT CTT GGA AAA GAA TAT GAT TCA GAA GAG AAT AAA TTG AGA ATG 336 Thr Ala Leu Gly Lys Glu Tyr Asp Ser Glu Glu Asn Lys Leu Arg Met 100 105 110 GCA ATA TTT GAA AGT AAT GAA TTA ATG ACA GAA GCA TTA AAT AGA AAA 384 Ala He Phe Glu Ser Asn Glu Leu Met Thr Glu Ala Leu Asn Arg Lys 115 120 125 TAT GAG CAA GGC TTA ATT TCA TTT AAA ACT GCC CTG AAT GAT ATG GCT 432 Tyr Glu Gin Gly Leu He Ser Phe Lys Thr Ala Leu Asn Asp Met Ala 130 135 140 GAT TTG ACC GAT CAA GAA TTC AAC CTA ATG AAT GGA CTT CTA CTG CAT 480 Asp Leu Thr Asp Gin Glu Phe Asn Leu Met Asn Gly Leu Leu Leu His 145 150 155 160 AAT GAA ACT TCC CAT ACA AGA AGG TAT GCT CGA CAA GTA TCT GGT GAA 528 Asn Glu Thr Ser His Thr Arg Arg Tyr Ala Arg Gin Val Ser Gly Glu 165 170 175 TTT CTC AAG TAC AAT AAG AGT ACA AAG CTG CCA AAA TAT GTT GAT TGG 576 Phe Leu Lys Tyr Asn Lys Ser Thr Lys Leu Pro Lys Tyr Val Asp Trp 180 185 190 AGA AAG AGA GGA TAT GTC ACA CCT GCC AAA GAG CAG GGC TTG TGT GGT 624 Arg Lys Arg Gly Tyr Val Thr Pro Ala Lys Glu Gin Gly Leu Cys Gly 195 200 205 AGT TGT TAT GCA TTC TGC AGC TGC AGC ATT AGA AGC CTT ATA TAT AAA 672 Ser Cys Tyr Ala Phe Cys Ser Cys Ser He Arg ser Leu He Tyr Lys 210 215 220 AAG ACG AAA AAC AAA CTT CTC GAT TTA TCT CCG CAA AAT ATT CTA GAT 720 Lys Thr Lys Asn Lys Leu Leu Asp Leu Ser Pro Gin Asn He Leu Asp 225 230 235 240 TGT ACA TGG GAT CTC GGT AAT AAT GGT TGC CAT GGT GGT TTC ATG AAT 768 Cys Thr Trp Asp Leu Gly Asn Asn Gly Cys His Gly Gly Phe Met Asn 245 250 255 CCG GCA TTT TAT TAT GCA AGT AAG GCA GGT ATT GCA TCA GAA GCG AAA 816 Pro Ala Phe Tyr Tyr Ala Ser Lys Ala Gly He Ala Ser Glu Ala Lys 260 265 270 TAT CCG TAT GTT CAC ACT GCA AGA CGT ACA TGC TAT TGG CGG AAA GAT 864 Tyr Pro Tyr Val His Thr Ala Arg Arg Thr Cys Tyr Trp Arg Lys Asp 275 280 285 ATA GTT GCT GCT ACT GAT AAT GGT TAC ACT CGA ATA CAA CAA GGT GAT 912 He Val Ala Ala Thr Asp Asn Gly Tyr Thr Arg He Gin Gin Gly Asp 290 295 300 GAG AAA GGT CTC AAT ATG CTG TGG CAA TTG ACC GTT GTT GTT GGA ATT 960. Glu Lys Gly Leu Asn Met Leu Trp Gin Leu Thr Val Val Val Gly He 305 310 315 320 TCT GGA TAT CAA CAC GAT TTT AAA TTT TAT AAA TCC GGT GTC TAC TCT 1008 Ser Gly Tyr Gin His Asp Phe Lys Phe Tyr Lys Ser Gly Val Tyr Ser 325 330 335 AGT GAT CAA TGT CGT GTT CCT AAT CAC GCA GTA CTG GTT GTT GGT TAT 1056 Ser Asp Gin Cys Arg Val Pro Asn His Ala Val Leu Val Val Gly Tyr 340 345 350 GGA ACC AGT CAA AAA ACA CGG GAT TAT TGG ATT ATT AAA AAT AGT TGG 1104 Gly Thr Ser Gin Lys Thr Arg Asp Tyr Trp He He Lys Asn Ser Trp 355 360 365 GGA ACT AAT TGG GCA AGA AAT GGA TAT GGT TAT ATG AAG 'JGA AAC GAA 1152 Gly Thr Asn Trp Ala Arg Asn Gly Tyr Gly Tyr Met Lys >Arg Asn Glu 370 375 380 AGG AAT ATG TGT CAT ATC GCT ACG ATG GCT TCA TTC CCC ATA 1194 Arg Asn Met Cys His He Ala Thr Met Ala Ser Phe Pro He 385 390 395 TAATTATGAT TTAATTTGTT TTCGAAAAAT ATTTATTTTG CTAATTTTCA ATATTTGATA 1254 ATTTTGGTTT AATAAAAAGA AATTGGGAAA AAAAAAAAAA AAAA 1298 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 398 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Leu Arg Phe He Ala Leu Leu Ala He Leu Thr Phe Leu He Asp Phe 1 5 10 15 Thr Val Ser Phe Asn Asp Glu He Leu Gin Leu Lys Glu Val Leu Gly 20 25 30 Met Phe Asp Glu Asp Tyr Arg Leu Gly Asn Met Thr Arg Leu Thr Phe 35 40 45 Asp Phe Gin Asn Ala Leu Lys Asp Tyr Gly Asp Gly Glu Asn Ser Tyr 50 55 60 Lys Leu Thr Ala Val Gin Ser Phe Leu Lys Lys Leu Glu Glu Asn Gly 65 70 75 80 Glu Glu Gin Ala Met Lys Lys Leu Glu Thr Glu Trp Gin Glu Tyr Leu 85 90 95 Thr Ala Leu Gly Lys Glu Tyr Asp Ser Glu Glu Asn Lys Leu Arg Met 100 105 110 Ala He Phe Glu Ser Asn Glu Leu Met Thr Glu Ala Leu Asn Arg Lys 115 120 125 Tyr Glu Gin Gly Leu He Ser Phe Lys Thr Ala Leu Asn Asp Met Ala 130 135 140 Asp Leu Thr Asp Gin Glu Phe Asn Leu Met Asn Gly Leu Leu Leu His 145 150 155 160 Asn Glu Thr Ser His Thr Arg Arg Tyr Ala Arg Gin Val Ser Gly Glu 165 170 175 Phe Leu Lys Tyr Asn Lys Ser Thr Lys Leu Pro Lys Tyr Val Asp Trp 180 185 190 Arg Lys Arg Gly Tyr Val Thr Pro Ala Lys Glu Gin Gly Leu Cys Gly 195 200 205 Ser Cys Tyr Ala Phe Cys Ser Cys Ser He Arg Ser Leu He Tyr Lys 210 215 220 Lys Thr Lys Asn Lys Leu Leu Asp Leu Ser Pro Gin Asn He Leu Asp 225 230 235 240 Cys Thr Trp Asp Leu Gly Asn Asn Gly Cys His Gly Gly Phe Met Asn 245 250 255 Pro Ala Phe Tyr Tyr Ala Ser Lys Ala Gly He Ala Ser Glu Ala Lys 260 265 270 Tyr Pro Tyr Val His Thr Ala Arg Arg Thr Cys Tyr Trp Arg Lys Asp 275 280 285 He Val Ala Ala Thr Asp Asn Gly Tyr Thr Arg He Gin Gin Gly Asp 290 295 300 Glu Lys Gly Leu Asn Met Leu Trp Gin Leu Thr Val Val Val Gly He 305 310 315 320 Ser Gly Tyr Gin His Asp Phe Lys Phe Tyr Lys Ser Gly Val Tyr Ser 325 330 335 Ser Asp Gin Cys Arg Val Pro Asn His Ala Val Leu Val Val Gly Tyr 340 345 350 Gly Thr Ser Gin Lys Thr Arg Asp Tyr Trp He He Lys Asn Ser Trp 355 360 365 Gly Thr Asn Trp Ala Arg Asn Gly Tyr Gly Tyr Met Lys Arg Asn Glu 370 375 380 Arg Asn Met Cys His He Ala Thr Met Ala Ser Phe Pro He 385 390 395 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 942 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..942 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ATG AAA AAA TTA GAA ACC GAA TGG CAA GAG TAT TTA ACA GCT CTT GGA 48 Met Lys Lys Leu Glu Thr Glu Trp Gin Glu Tyr Leu Thr Ala Leu Gly 1 5 10 15 AAA GAA TAT GAT TCA GAA GAG AAT AAA TTG AGA ATG GCA ATA TTT GAA 96 Lys Glu Tyr Asp Ser Glu Glu Asn Lys Leu Arg Met Ala He Phe Glu 20 25 30 AGT AAT GAA TTA ATG ACA GAA GCA TTA AAT AGA AAA TAT GAG CAA GGC 144 Ser Asn Glu Leu Met Thr Glu Ala Leu Asn Arg Lys Tyr Glu Gin Gly 35 40 45 TTA ATT TCA TTT AAA ACT GCC CTG AAT GAT ATG GCT GAT TTG ACC GAT 192 Leu He Ser Phe Lys Thr Ala Leu Asn Asp Met Ala Asp Leu Thr Asp 50 55 60 CAA GAA TTC AAC CTA ATG AAT GGA CTT CTA CTG CAT AAT GAA ACT TCC 240 Gin Glu Phe Asn Leu Met Asn Gly Leu Leu Leu His Asn Glu Thr Ser 65 70 75 80 CAT ACA AGA AGG TAT GCT CGA CAA GTA TCT GGT GAA TTT CTC AAG TAC 288 His Thr Arg Arg Tyr Ala Arg Gin Val Ser Gly Glu Phe Leu Lys Tyr 85 90 95 AAT AAG AGT ACA AAG CTG CCA AAA TAT GTT GAT TGG AGA AAG AGA GGA 336 Asn Lys Ser Thr Lys Leu Pro Lys Tyr Val Asp Trp Arg Lys Arg Gly 100 105 110 TAT GTC ACA CCT GCC AAA GAG CAG GGC TTG TGT GGT AGT TGT TAT GCA 384 Tyr Val Thr Pro Ala Lys Glu Gin Gly Leu Cys Gly Ser Cys Tyr Ala 115 120 125 TTC TGC AGC TGC AGC ATT AGA AGC CTT ATA TAT AAA AAG ACG AAA AAC 432 Phe Cys Ser Cys Ser He Arg Ser Leu He Tyr Lys Lys Thr Lys Asn 130 135 140 AAA CTT CTC GAT TTA TCT CCG CAA AAT ATT CTA GAT TGT ACA TGG GAT 480 Lys Leu Leu Asp Leu Ser Pro Gin Asn He Leu Asp Cys Thr Trp Asp 145 150 155 160 CTC GGT AAT AAT GGT TGC CAT GGT GGT TTC ATG AAT CCG GCA TTT TAT 528 Leu Gly Asn Asn Gly Cys His Gly Gly Phe Met Asn Pro Ala Phe Tyr 165 170 175 TAT GCA AGT AAG GCA GGT ATT GCA TCA GAA GCG AAA TAT CCG TAT GTT 576 Tyr Ala Ser Lys Ala Gly He Ala Ser Glu Ala Lys Tyr Pro Tyr Val 180 185 190 CAC ACT GCA AGA CGT ACA TGC TAT TGG CGG AAA GAT ATA GTT GCT GCT 624 His Thr Ala Arg Arg Thr Cys Tyr Trp Arg Lys Asp He Val Ala Ala 195 200 205 ACT GAT AAT GGT TAC ACT CGA ATA CAA CAA GGT GAT GAG AAA GGT CTC 672 Thr Asp Asn Gly Tyr Thr Arg He Gin Gin Gly Asp Glu Lys Gly Leu 210 215 220 AAT ATG CTG TGG CAA TTG ACC GTT GTT GTT GGA ATT TCT GGA TAT CAA 720 Asn Met Leu Trp Gin Leu Thr Val Val Val Gly He Ser Gly Tyr Gin 225 230 235 240 CAC GAT TTT AAA TTT TAT AAA TCC GGT GTC TAC TCT AGT GAT CAA TGT 768 His Asp Phe Lys Phe Tyr Lys Ser Gly Val Tyr Ser Ser Asp Gin Cys 245 250 255 CGT GTT CCT AAT CAC GCA GTA CTG GTT GTT GGT TAT GGA ACC AGT CAA 816 Arg Val Pro Asn His Ala Val Leu Val Val Gly Tyr Gly Thr Ser Gin 260 265 270 AAA ACA CGG GAT TAT TGG ATT ATT AAA AAT AGT TGG GGA ACT AAT TGG 864 Lys Thr Arg Asp Tyr Trp He He Lys Asn Ser Trp Gly Thr Asn Trp 275 280 285 GCA AGA AAT GGA TAT GGT TAT ATG AAG CGA AAC GAA AGG AAT ATG TGT 912 Ala Arg Asn Gly Tyr Gly Tyr Met Lys Arg Asn Glu Arg Asn Met Cys 290 295 300 CAT ATC GCT ACG ATG GCT TCA TTC CCC ATA 942 His He Ala Thr Met Ala Ser Phe Pro He 305 310 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 314 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Lys Lys Leu Glu Thr Glu Trp Gin Glu Tyr Leu Thr Ala Leu Gly 1 5 10 15 Lys Glu Tyr Asp Ser Glu Glu Asn Lys Leu Arg Met Ala He Phe Glu 20 25 30 Ser Asn Glu Leu Met Thr Glu Ala Leu Asn Arg Lys Tyr Glu Gin Gly 35 40 45 Leu He Ser Phe Lys Thr Ala Leu Asn Asp Met Ala Asp Leu Thr Asp 50 55 60 Gin Glu Phe Asn Leu Met Asn Gly Leu Leu Leu His Asn Glu Thr Ser 65 70 75 80 His Thr Arg Arg Tyr Ala Arg Gin Val Ser Gly Glu Phe Leu Lys Tyr 85 90 95 Asn Lys Ser Thr Lys Leu Pro Lys Tyr Val Asp Trp Arg Lys Arg Gly 100 105 110 Tyr Val Thr Pro Ala Lys Glu Gin Gly Leu Cys Gly Ser Cys Tyr Ala 115 120 125 Phe Cys Ser Cys Ser He Arg Ser Leu He Tyr Lys Lys Thr Lys Asn 130 135 140 Lys Leu Leu Asp Leu Ser Pro Gin Asn He Leu Asp Cys Thr Trp Asp 145 150 155 160 Leu Gly Asn Asn Gly Cys His Gly Gly Phe Met Asn Pro Ala Phe Tyr 165 170 175 Tyr Ala Ser Lys Ala Gly He Ala Ser Glu Ala Lys Tyr Pro Tyr Val 180 185 190 His Thr Ala Arg Arg Thr Cys Tyr Trp Arg Lys Asp He Val Ala Ala 195 200 205 Thr Asp Asn Gly Tyr Thr Arg He Gin Gin Gly Asp Glu Lys Gly Leu 210 215 220 Asn Met Leu Trp Gin Leu Thr Val Val Val Gly He Ser Gly Tyr Gin 225 230 235 240 His Asp Phe Lys Phe Tyr Lys Ser Gly Val Tyr Ser Ser Asp Gin Cys 245 250 255 Arg Val Pro Asn His Ala Val Leu Val Val Gly Tyr Gly Thr Ser Gin 260 265 270 Lys Thr Arg Asp Tyr Trp He He Lys Asn Ser Trp Gly Thr Asn Trp 275 280 285 Ala Arg Asn Gly Tyr Gly Tyr Met Lys Arg Asn Glu Arg Asn Met Cys 290 295 300 His He Ala Thr Met Ala Ser Phe Pro He 305 310 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 291 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..219 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: T ATG AGA TTC TAT AAA TCC GGT GTT TAT TCT AAT CGT GAC TGT GGT 46 Met Arg Phe Tyr Lys Ser Gly Val Tyr Ser Asn Arg Asp Cys Gly 1 5 10 15 GAT CTT AAT CAC GCA GTA CTA CTT GTC GGT TAT GGC AAG CAT AAA ACA 94 Asp Leu Asn His Ala Val Leu Leu Val Gly Tyr Gly Lys His Lys Thr 20 25 30 TAC GGA GAA TAC TGG ATT ATT AAA AAC AGC TGG GGA ACT GAT TGG GGA 142 Tyr Gly Glu Tyr Trp He He Lys Asn Ser Trp Gly Thr Asp Trp Gly 35 40 45 AGA AAA GGA TAC GCT TAT ATG GCG CGA AAT AAG GGG AAC ATG TGC CAC 190 Arg Lys Gly Tyr Ala Tyr Met Ala Arg Asn Lys Gly Asn Met Cys His 50 55 60 ATC GCA ACG TTG GCT TCA ATA CCC ATA TA AAAATGATTA AATTTGATTT 239 He Ala Thr Leu Ala Ser He Pro He 65 70 TGAATAGTAT TTATTGGCCA AATTCTAACT TTCATCTATG TTTGAGGGCA AT 291 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 72 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Arg Phe Tyr Lys Ser Gly Val Tyr Ser Asn Arg Asp Cys Gly Asp 1 5 10 15 Leu Asn His Ala Val Leu Leu Val Gly Tyr Gly Lys His Lys Thr Tyr 20 25 30 Gly Glu Tyr Trp He He Lys Asn Ser Trp Gly Thr Asp Trp Gly Arg 35 40 45 Lys Gly Tyr Ala Tyr Met Ala Arg Asn Lys Gly Asn Met Cys His He 50 55 60 Ala Thr Leu Ala Ser He Pro He 65 70 (2) INFORMATION FOR SEQ ID NO:7: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 216 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: TTTAGATTCT ATAAATCCGG TGTTTATTCT AATCGTGACT GTGGTGATCT TAATCACGCA 60 GTACTACTTG TCGGTTATGG CAAGCATAAA ACATACGGAG AATACTGGAT TATTAAAAAC 120 AGCTGGGGAA CTGATTGGGG AAGAAAAGGA TACGCTTATA TGGCGCGAAA TAAGGGGAAC 180 ATGTGCCACA TCGCAACGTT GGCTTCAATA CCCATA 216 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: AACGGTGAGG ATCCAGCGAT GAAAAAATTA GAAAC 35 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: ATTAAAAGAT CTTTATATGG GGAATGAAGC CATCG 35 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: CGCGGATCCT ATAAATATGA AAAAATTAGA AACC 34 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: CGCGGATCCT TATATGGGGA ATGAAGC 27 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..17 (D) OTHER INFORMATION: /label= primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: CATGTTCCCC TTATTTC 17 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..17 (D) OTHER INFORMATION: /label= primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: CATGTTCCCC TTATTTC 17 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1306 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..1223 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: C AGA AGC AGA AAA AAA CTC ATG CTT CGG ATC ATT GTT TTA CTG ATC 46 Arg Ser Arg Lys Lys Leu Met Leu Arg He He Val Leu Leu He 1 5 10 15 GTA TTC GCC TTC CTA GTC GAT TTT ACT GTC ACA CTC AAT GCC CAA GTG 94 Val Phe Ala Phe Leu Val Asp Phe Thr Val Thr Leu Asn Ala Gin Val 20 25 30 CAA CAG CTA CGA GAA GTT CTA GGA ACA TTT GAT CAA GAT TAC AAG CGA 142 Gin Gin Leu Arg Glu Val Leu Gly Thr Phe Asp Gin Asp Tyr Lys Arg 35 40 45 GGC AAT ATG ACG AGG CTT ACG ACT GAT TTC AAA AAA GCA GTA AAA AAA 190 Gly Asn Met Thr Arg Leu Thr Thr Asp Phe Lys Lys Ala Val Lys Lys 50 55 60 TAC GGC GAT GGA AAA GAA AGT CAA AAA TCA ACC GTT CTG CAA TCT TTT 238 Tyr Gly Asp Gly Lys Glu Ser Gin Lys Ser Thr Val Leu Gin Ser Phe 65 70 75 CTT CAA AAA ATG GAA GAC AAT GGC GAG CTA CGA GCT ATG GAG AAA TTA 286 Leu Gin Lys Met Glu Asp Asn Gly Glu Leu Arg Ala Met Glu Lys Leu 80 85 90 95 GAA ACC GAA TGG AAT GAT TAC GTA ATG GCT CTC GGA AAA CAC TAC GAC 334 Glu Thr Glu Trp Asn Asp Tyr Val Met Ala Leu Gly Lys His Tyr Asp 100 105 110 TCA AAT GAG TCC AAT TTG AGA ATG GCA ATA TTT GAA AGT AAT GAA TTA 382 Ser Asn Glu Ser Asn Leu Arg Met Ala He Phe Glu Ser Asn Glu Leu 115 120 125 ATG ACA GAA GCC ACA AAT AGA AAA TAT GAA CAA GGC CTA ATT TCT TAT 430 Met Thr Glu Ala Thr Asn Arg Lys Tyr Glu Gin Gly Leu He Ser Tyr 130 135 140 ACA AAT GGT CTG AAT CAC TTG GCT GAT TTG ACC GAC GAA GAA TTC AAA 478 Thr Asn Gly Leu Asn His Leu Ala Asp Leu Thr Asp Glu Glu Phe Lys 145 150 155 ATG ATG AAT GGA CTT CGT TTT CCC AAT GAA ACT CAT CTT CGA ACA AGA 526 Met Met Asn Gly Leu Arg Phe Pro Asn Glu Thr His Leu Arg Thr Arg 160 165 170 175 AGG CAG ACT CGT CAT ACT GTA GGT CAA AAA TAT ACG TAC GAT CCA AAT 574 Arg Gin Thr Arg His Thr Val Gly Gin Lys Tyr Thr Tyr Asp Pro Asn 180 185 190 GAG AAA CTG CCG GTG TCG GTT GAC TGG AGA AAG AAA GGC ATG GTC ACA 622 Glu Lys Leu Pro Val Ser Val Asp Trp Arg Lys Lys Gly Met Val Thr 195 200 205 CCC GTC AAA AAT CAA GGA GTG TGT GGC AGC TGC TAT CGA TTC GCT GCA 670 Pro Val Lys Asn Gin Gly Val Cys Gly Ser Cys Tyr Arg Phe Ala Ala 210 215 220 ATA GGT GCA TTG GAA GCT TAT AAT AAG AAA AAG ACA GGG AAA CTT GTC 718 He Gly Ala Leu Glu Ala Tyr Asn Lys Lys Lys Thr Gly Lys Leu Val 225 230 235 GAT TTA TCC ATC CAA AAT GCT GTT GAC TGC ACA TGG ACG TTG GGT AAC 766 Asp Leu Ser He Gin Asn Ala Val Asp Cys Thr Trp Thr Leu Gly Asn 240 245 250 255 TAT GGC TGT CGT GGT GGC TAT ATG AAT CCA ATT TTC TAT TAT GCA ACG 814 Tyr Gly Cys Arg Gly Gly Tyr Met Asn Pro He Phe Tyr Tyr Ala Thr 260 265 270 AAG TTT GGA TTA GCG ATG GAA TCG AAA TAT CCG TAC GTT GGG ACT GAA 862 Lys Phe Gly Leu Ala Met Glu Ser Lys Tyr Pro Tyr Val Gly Thr Glu 275 280 285 CAA AAA TGC AAA TGG CAA GAG AAA ATT TGT TAC GCC ACT GAT AAG GGT 910 Gin Lys Cys Lys Trp Gin Glu Lys He Cys Tyr Ala Thr Asp Lys Gly 290 295 300 TAC GCT GCA ATA CAA AGG GGT GAT GAA TTA GGA CTT ATG CAT GCT GTG 958 Tyr Ala Ala He Gin Arg Gly Asp Glu Leu Gly Leu Met His Ala Val 305 310 315 GCT AAG CAT GGA CCC GTT GTT GTT GGA ATT AAC GGA TCA AAG CGT CCT 1006 Ala Lys His Gly Pro Val Val Val Gly He Asn Gly Ser Lys Arg Pro 320 325 330 335 TTT AGA TTC TAT AAA TCC GGT GTT TAT TCT AAT CGT GAC TGT GGT GAT 1054 Phe Arg Phe Tyr Lys Ser Gly Val Tyr Ser Asn Arg Asp Cys Gly Asp 340 345 350 CTT AAT CAC GCA GTA CTA CTT GTC GGT TAT GGC AAG CAT AAA ACG TAC 1102 Leu Asn His Ala Val Leu Leu Val Gly Tyr Gly Lys His Lys Thr Tyr 355 360 365 GGA GAA TAC TGG ATT ATT AAA AAC AGC TGG GGA ACT GAT TGG GGA AGA 1150 Gly Glu Tyr Trp He He Lys Asn Ser Trp Gly Thr Asp Trp Gly Arg 370 375 380 AAA GGA TAC GCT TAT ATG GCG CGA AAT AAG GGG AAC ATG TGC CAC ATC 1198 Lys Gly Tyr Ala Tyr Met Ala Arg Asn Lys Gly Asn Met Cys His He 385 390 395 GCA ACG TTG GCT TCA ATA CCC ATA T AAAAATGATT AAATTTGATT 1243 Ala Thr Leu Ala Ser He Pro He 400 405 TTGAATAGTA TTTATTGGCC AAATTCTAAC TTTCATCTAT GTTTGAGGGC AATAATTTGC 1303 GGC 1306 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 407 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Arg Ser Arg Lys Lys Leu Met Leu Arg He He Val Leu Leu He Val 1 5 10 15 Phe Ala Phe Leu Val Asp Phe Thr Val Thr Leu Asn Ala Gin Val Gin 20 25 30 Gin Leu Arg Glu Val Leu Gly Thr Phe Asp Gin Asp Tyr Lys Arg Gly 35 40 45 Asn Met Thr Arg Leu Thr Thr Asp Phe Lys Lys Ala Val Lys Lys Tyr 50 55 60 Gly Asp Gly Lys Glu Ser Gin Lys Ser Thr Val Leu Gin Ser Phe Leu 65 70 75 80 Gin Lys Met Glu Asp Asn Gly Glu Leu Arg Ala Met Glu Lys Leu Glu 85 90 95 Thr Glu Trp Asn Asp Tyr Val Met Ala Leu Gly Lys His Tyr Asp Ser 100 105 110 Asn Glu Ser Asn Leu Arg Met Ala He Phe Glu Ser Asn Glu Leu Met 115 120 125 Thr Glu Ala Thr Asn Arg Lys Tyr Glu Gin Gly Leu He Ser Tyr Thr 130 135 140 Asn Gly Leu Asn His Leu Ala Asp Leu Thr Asp Glu Glu Phe Lys Met 145 150 155 160 Met Asn Gly Leu Arg Phe Pro Asn Glu Thr His Leu Arg Thr Arg Arg 165 170 175 Gin Thr Arg His Thr Val Gly Gin Lys Tyr Thr Tyr Asp Pro Asn Glu 180 185 190 Lys Leu Pro Val Ser Val Asp Trp Arg Lys Lys Gly Met Val Thr Pro 195 200 205 Val Lys Asn Gin Gly Val Cys Gly Ser Cys Tyr Arg Phe Ala Ala He 210 215 220 Gly Ala Leu Glu Ala Tyr Asn Lys Lys Lys Thr Gly Lys Leu Val Asp 225 230 235 240 Leu Ser He Gin Asn Ala Val Asp Cys Thr Trp Thr Leu Gly Asn Tyr 245 250 255 Gly Cys Arg Gly Gly Tyr Met Asn Pro He Phe Tyr Tyr Ala Thr Lys 260 265 270 Phe Gly Leu Ala Met Glu Ser Lys Tyr Pro Tyr Val Gly Thr Glu Gin 275 280 285 Lys Cys Lys Trp Gin Glu Lys He Cys Tyr Ala Thr Asp Lys Gly Tyr 290 295 300 Ala Ala He Gin Arg Gly Asp Glu Leu Gly Leu Met His Ala Val Ala 305 310 315 320 Lys His Gly Pro Val Val Val Gly He Asn Gly Ser Lys Arg Pro Phe 325 330 335 Arg Phe Tyr Lys Ser Gly Val Tyr Ser Asn Arg Asp Cys Gly Asp Leu 340 345 350 Asn His Ala Val Leu Leu Val Gly Tyr Gly Lys His Lys Thr Tyr Gly 355 360 365 Glu Tyr Trp He He Lys Asn Ser Trp Gly Thr Asp Trp Gly Arg Lys 370 375 380 Gly Tyr Ala Tyr Met Ala Arg Asn Lys Gly Asn Met Cys His He Ala 385 390 395 400 Thr Leu Ala Ser He Pro He 405 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1203 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1203 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: ATG CTT CGG ATC ATT GTT TTA CTG ATC GTA TTC GCC TTC CTA GTC GAT 48 Met Leu Arg He He Val Leu Leu He Val Phe Ala Phe Leu Val Asp 1 5 10 15 TTT ACT GTC ACA CTC AAT GCC CAA GTG CAA CAG CTA CGA GAA GTT CTA 96 Phe Thr Val Thr Leu Asn Ala Gin Val Gin Gin Leu Arg Glu Val Leu 20 25 30 GGA ACA TTT GAT CAA GAT TAC AAG CGA GGC AAT ATG ACG AGG CTT ACG 144 Gly Thr Phe Asp Gin Asp Tyr Lys Arg Gly Asn Met Thr Arg Leu Thr 35 40 45 ACT GAT TTC AAA AAA GCA GTA AAA AAA TAC GGC GAT GGA AAA GAA AGT 192 Thr Asp Phe Lys Lys Ala Val Lys Lys Tyr Gly Asp Gly Lys Glu Ser 50 55 60 CAA AAA TCA ACC GTT CTG CAA TCT TTT CTT CAA AAA ATG GAA GAC AAT 240 Gin Lys Ser Thr Val Leu Gin Ser Phe Leu Gin Lys Met Glu Asp Asn 65 70 75 80 GGC GAG CTA CGA GCT ATG GAG AAA TTA GAA ACC GAA TGG AAT GAT TAC 288 Gly Glu Leu Arg Ala Met Glu Lys Leu Glu Thr Glu Trp Asn Asp Tyr 85 90 95 GTA ATG GCT CTC GGA AAA CAC TAC GAC TCA AAT GAG TCC AAT TTG AGA 336 Val Met Ala Leu Gly Lys His Tyr Asp Ser Asn Glu Ser Asn Leu Arg 100 105 110 ATG GCA ATA TTT GAA AGT AAT GAA TTA ATG ACA GAA GCC ACA AAT AGA 384 Met Ala He Phe Glu Ser Asn Glu Leu Met Thr Glu Ala Thr Asn Arg 115 120 125 AAA TAT GAA CAA GGC CTA ATT TCT TAT ACA AAT GGT CTG AAT CAC TTG 432 Lys Tyr Glu Gin Gly Leu He Ser Tyr Thr Asn Gly Leu Asn His Leu 130 135 140 GCT GAT TTG ACC GAC GAA GAA TTC AAA ATG ATG AAT GGA CTT CGT TTT 480 Ala Asp Leu Thr Asp Glu Glu Phe Lys Met Met Asn Gly Leu Arg Phe 145 150 155 160 CCC AAT GAA ACT CAT CTT CGA ACA AGA AGG CAG ACT CGT CAT ACT GTA 528 Pro Asn Glu Thr His Leu Arg Thr Arg Arg Gin Thr Arg His Thr Val 165 170 175 GGT CAA AAA TAT ACG TAC GAT CCA AAT GAG AAA CTG CCG GTG TCG GTT 576 Gly Gin Lys Tyr Thr Tyr Asp Pro Asn Glu Lys Leu Pro Val Ser Val 180 185 190 GAC TGG AGA AAG AAA GGC ATG GTC ACA CCC GTC AAA AAT CAA GGA GTG 624 Asp Trp Arg Lys Lys Gly Met Val Thr Pro Val Lys Asn Gin Gly Val 195 200 205 TGT GGC AGC TGC TAT CGA TTC GCT GCA ATA GGT GCA TTG GAA GCT TAT 672 Cys Gly Ser Cys Tyr Arg Phe Ala Ala He Gly Ala Leu Glu Ala Tyr 210 215 220 AAT AAG AAA AAG ACA GGG AAA CTT GTC GAT TTA TCC ATC CAA AAT GCT 720 Asn Lys Lys Lys Thr Gly Lys Leu Val Asp Leu Ser He Gin Asn Ala 225 230 235 240 GTT GAC TGC ACA TGG ACG TTG GGT AAC TAT GGC TGT CGT GGT GGC TAT 768 Val Asp Cys Thr Trp Thr Leu Gly Asn Tyr Gly Cys Arg Gly Gly Tyr 245 250 255 ATG AAT CCA ATT TTC TAT TAT GCA ACG AAG TTT GGA TTA GCG ATG GAA 816 Met Asn Pro He Phe Tyr Tyr Ala Thr Lys Phe Gly Leu Ala Met Glu 260 265 270 TCG AAA TAT CCG TAC GTT GGG ACT GAA CAA AAA TGC AAA TGG CAA GAG 864 Ser Lys Tyr Pro Tyr Val Gly Thr Glu Gin Lys Cys Lys Trp Gin Glu 275 280 285 AAA ATT TGT TAC GCC ACT GAT AAG GGT TAC GCT GCA ATA CAA AGG GGT 912 Lys He Cys Tyr Ala Thr Asp Lys Gly Tyr Ala Ala He Gin Arg Gly 290 295 300 GAT GAA TTA GGA CTT ATG CAT GCT GTG GCT AAG CAT GGA CCC GTT GTT 960 Asp Glu Leu Gly Leu Met His Ala Val Ala Lys His Gly Pro Val Val 305 310 315 320 GTT GGA ATT AAC GGA TCA AAG CGT CCT TTT AGA TTC TAT AAA TCC GGT 1008 Val Gly He Asn Gly Ser Lys Arg Pro Phe Arg Phe Tyr Lys Ser Gly 325 330 335 GTT TAT TCT AAT CGT GAC TGT GGT GAT CTT AAT CAC GCA GTA CTA CTT 1056 Val Tyr Ser Asn Arg Asp Cys Gly Asp Leu Asn His Ala Val Leu Leu 340 345 350 GTC GGT TAT GGC AAG CAT AAA ACG TAC GGA GAA TAC TGG ATT ATT AAA 1104 Val Gly Tyr Gly Lys His Lys Thr Tyr Gly Glu Tyr Trp He He Lys 355 360 365 AAC AGC TGG GGA ACT GAT TGG GGA AGA AAA GGA TAC GCT TAT ATG GCG 1152 Asn Ser Trp Gly Thr Asp Trp Gly Arg Lys Gly Tyr Ala Tyr Met Ala 370 375 380 CGA AAT AAG GGG AAC ATG TGC CAC ATC GCA ACG TTG GCT TCA ATA CCC 1200 Arg Asn Lys Gly Asn Met Cys His He Ala Thr Leu Ala Ser He Pro 385 390 395 400 ATA 1203 He (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..30 (D) OTHER INFORMATION: /label= primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: CGGGGTACCA GGAAATATGA CGAGACTTAC 30 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..27 ( i) SEQUENCE DESCRIPTION: SEQ ID NO:18: CGGGGTACCT TATATGGGGA ATGAAGC 27 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 49 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..49 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: GATCCAATTG GATCAGCTTT TTTTTTTTTT TTTTTGGCAT ATAAATAAG 49 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 49 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..49 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: GTACCTTATT TATATGCCAA AAAAAAAAAA AAAAAAGCTG ATCCAATTG 49 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 213 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Leu Pro Lys Tyr Val Asp Trp Arg Lys Arg Gly Tyr Val Thr Pro Ala 1 5 10 15 Lys Glu Gin Gly Leu Cys Gly Ser Cys Tyr Ala Phe Cys Ser Cys Ser 20 25 30 He Arg Ser Leu He Tyr Lys Lys Thr Lys Asn Lys Leu Leu Asp Leu 35 40 45 Ser Pro Gin Asn He Leu Asp Cys Thr Trp Asp Leu Gly Asn Asn Gly 50 55 60 Cys His Gly Gly Phe Met Asn Pro Ala Phe Tyr Tyr Ala Ser Lys Ala 65 70 75 80 Gly He Ala Ser Glu Ala Lys Tyr Pro Tyr Val His Thr Ala Arg Arg 85 90 95 Thr Cys Tyr Trp Arg Lys Asp He Val Ala Ala Thr Asp Asn Gly Tyr 100 105 110 Thr Arg He Gin Gin Gly Asp Glu Lys Gly Leu Asn Met Leu Trp Gin 115 120 125 Leu Thr Val Val Val Gly He Ser Gly Tyr Gin His Asp Phe Lys Phe 130 135 140 Tyr Lys Ser Gly Val Tyr Ser Ser Asp Gin Cys Arg Val Pro Asn His 145 150 155 160 Ala Val Leu Val Val Gly Tyr Gly Thr Ser Gin Lys Thr Arg Asp Tyr 165 170 175 Trp He He Lys Asn Ser Trp Gly Thr Asn Trp Ala Arg Asn Gly Tyr 180 185 190 Gly Tyr Met Lys Arg Asn Glu Arg Asn Met Cys His He Ala Thr Met 195 200 205 Ala Ser Phe Pro He 210 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..32 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: ACTGGATCCG CAAGTGCAAC AGCTACGAGA AG 32 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 63 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1..63 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: TAAGGTACCT TATATGGGTA TTGAAGCCAA CGTTGCGATG TGGCACATGT TCCCCTTATT 60 TCG 63 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 356 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1172 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Met Thr Arg Leu Thr Phe Asp Phe Gin Asn Ala Leu Lys Asp Tyr Gly 1 5 10 15 Asp Gly Glu Asn Ser Tyr Lys Leu Thr Ala Val Gin Ser Phe Leu Lys 20 25 30 Lys Leu Glu Glu Asn Gly Glu Glu Gin Ala Met Lys Lys Leu Glu Thr 35 40 45 Glu Trp Gin Glu Tyr Leu Thr Ala Leu Gly Lys Glu Tyr Asp Ser Glu 50 55 60 Glu Asn Lys Leu Arg Met Ala He Phe Glu Ser Asn Glu Leu Met Thr 65 70 75 80 Glu Ala Leu Asn Arg Lys Tyr Glu Gin Gly Leu He Ser Phe Lys Thr 85 90 95 Ala Leu Asn Asp Met Ala Asp Leu Thr Asp Gin Glu Phe Asn Leu Met 100 105 110 Asn Gly Leu Leu Leu His Asn Glu Thr Ser His Thr Arg Arg Tyr Ala 115 120 125 Arg Gin Val Ser Gly Glu Phe Leu Lys Tyr Asn Lys Ser Thr Lys Leu 130 135 140 Pro Lys Tyr Val Asp Trp Arg Lys Arg Gly Tyr Val Thr Pro Ala Lys 145 150 155 160 Glu Gin Gly Leu Cys Gly Ser Cys Tyr Ala Phe Cys Ser Cys Ser He 165 170 175 Arg Ser Leu He Tyr Lys Lys Thr Lys Asn Lys Leu Leu Asp Leu Ser 180 185 190 Pro Gin Asn He Leu Asp Cys Thr Trp Asp Leu Gly Asn Asn Gly Cys 195 200 205 His Gly Gly Phe Met Asn Pro Ala Phe Tyr Tyr Ala Ser Lys Ala Gly 210 215 220 He Ala Ser Glu Ala Lys Tyr Pro Tyr Val His Thr Ala Arg Arg Thr 225 230 235 240 Cys Tyr Trp Arg Lys Asp He Val Ala Ala Thr Asp Asn Gly Tyr Thr 245 250 255 Arg He Gin Gin Gly Asp Glu Lys Gly Leu Asn Met Leu Trp Gin Leu 260 265 270 Thr Val Val Val Gly He Ser Gly Tyr Gin His Asp Phe Lys Phe Tyr 275 280 285 Lys Ser Gly Val Tyr Ser Ser Asp Gin Cys Arg Val Pro Asn His Ala 290 295 300 Val Leu Val Val Gly Tyr Gly Thr Ser Gin Lys Thr Arg Asp Tyr Trp 305 310 315 320 He He Lys Asn Ser Trp Gly Thr Asn Trp Ala Arg Asn Gly Tyr Gly 325 330 335 Tyr Met Lys Arg Asn Glu Arg Asn Met Cys His He Ala Thr Met Ala 340 345 350 Ser Phe Pro He 355 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1298 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: TTTTTTTTTT TTTTTTTCCC AATTTCTTTT TATTAAACCA AAATTATCAA ATATTGAAAA 60 TTAGCAAAAT AAATATTTTT CGAAAACAAA TTAAATCATA ATTATATGGG GAATGAAGCC 120 ATCGTAGCGA TATGACACAT ATTCCTTTCG TTTCGCTTCA TATAACCATA TCCATTTCTT 180 GCCCAATTAG TTCCCCAACT ATTTTTAATA ATCCAATAAT CCCGTGTTTT TTGACTGGTT 240 CCATAACCAA CAACCAGTAC TGCGTGATTA GGAACACGAC ATTGATCACT AGAGTAGACA 300 CCGGATTTAT AAAATTTAAA ATCGTGTTGA TATCCAGAAA TTCCAACAAC AACGGTCAAT 360 TGCCACAGCA TATTGAGACC TTTCTCATCA CCTTGTTGTA TTCGAGTGTA ACCATTATCA 420 GTAGCAGCAA CTATATCTTT CCGCCAATAG CATGTACGTC TTGCAGTGTG AACATACGGA 480 TATTTCGCTT CTGATGCAAT ACCTGCCTTA CTTGCATAAT AAAATGCCGG ATTCATGAAA 540 CCACCATGGC AACCATTATT ACCGAGATCC CATGTACAAT CTAGAATATT TTGCGGAGAT 600 AAATCGAGAA GTTTGTTTTT CGTCTTTTTA TATATAAGGC TTCTAATGCT GCAGCTGCAG 660 AATGCATAAC AACTACCACA CAAGCCCTGC TCTTTGGCAG GTGTGACATA TCCTCTCTTT 720 CTCCAATCAA CATATTTTGG CAGCTTTGTA CTCTTATTGT ACTTGAGAAA TTCACCAGAT 780 ACTTGTCGAG CATACCTTCT TGTATGGGAA GTTTCATTAT GCAGTAGAAG TCCATTCATT 840 AGGTTGAATT CTTGATCGGT CAAATCAGCC ATATCATTCA GGGCAGTTTT AAATGAAATT 900 AAGCCTTGCT CATATTTTCT ATTTAATGCT TCTGTCATTA ATTCATTACT TTCAAATATT 960 GCCATTCTCA ATTTATTCTC TTCTGAATCA TATTCTTTTC CAAGAGCTGT TAAATACTCT 1020 TGCCATTCGG TTTCTAATTT TTTCATCGCT TGTTCCTCAC CGTTTTCTTC TAATTTTTTG 1080 AGGAAAGATT GCACAGCAGT TAGTTTATAA CTGTTTTCTC CATCGCCGTA ATCTTTCAAA 1140 GCGTTTTGAA AATCAAACGT AAGTCTCGTC ATATTTCCTA ATCTGTAATC TTCATCAAAC 1200 ATTCCCAATA CTTCTTTCAG CTGTAGAATT TCATCATTGA ATGAGACGGT AAAGTCGATC 1260 AAGAAAGTGA GTATGGCCAA TAAAGCAATG AATCGAAG 1298 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1046 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: ττττττττττ TTTTTTTCCC AATTTCTTTT TATTAAACCA AAATTATCAA ATATTGAAAA 60 TTAGCAAAAT AAATATTTTT CGAAAACAAA TTAAATCATA ATTATATGGG GAATGAAGCC 120 ATCGTAGCGA TATGACACAT ATTCCTTTCG TTTCGCTTCA TATAACCATA TCCATTTCTT 180 GCCCAATTAG TTCCCCAACT ATTTTTAATA ATCCAATAAT CCCGTGTTTT TTGACTGGTT 240 CCATAACCAA CAACCAGTAC TGCGTGATTA GGAACACGAC ATTGATCACT AGAGTAGACA 300 CCGGATTTAT AAAATTTAAA ATCGTGTTGA TATCCAGAAA TTCCAACAAC AACGGTCAAT 360 TGCCACAGCA TATTGAGACC TTTCTCATCA CCTTGTTGTA TTCGAGTGTA ACCATTATCA 420 GTAGCAGCAA CTATATCTTT CCGCCAATAG CATGTACGTC TTGCAGTGTG AACATACGGA 480 TATTTCGCTT CTGATGCAAT ACCTGCCTTA CTTGCATAAT AAAATGCCGG ATTCATGAAA 540 CCACCATGGC AACCATTATT ACCGAGATCC CATGTACAAT CTAGAATATT TTGCGGAGAT 600 AAATCGAGAA GTTTGTTTTT CGTCTTTTTA TATATAAGGC TTCTAATGCT GCAGCTGCAG 660 AATGCATAAC AACTACCACA CAAGCCCTGC TCTTTGGCAG GTGTGACATA TCCTCTCTTT 720 CTCCAATCAA CATATTTTGG CAGCTTTGTA CTCTTATTGT ACTTGAGAAA TTCACCAGAT 780 ACTTGTCGAG CATACCTTCT TGTATGGGAA GTTTCATTAT GCAGTAGAAG TCCATTCATT 840 AGGTTGAATT CTTGATCGGT CAAATCAGCC ATATCATTCA GGGCAGTTTT AAATGAAATT 900 AAGCCTTGCT CATATTTTCT ATTTAATGCT TCTGTCATTA ATTCATTACT TTCAAATATT 960 GCCATTCTCA ATTTATTCTC TTCTGAATCA TATTCTTTTC CAAGAGCTGT TAAATACTCT 1020 TGCCATTCGG TTTCTAATTT TTTCAT 1046 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 291 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: ATTGCCCTCA AACATAGATG AAAGTTAGAA TTTGGCCAAT AAATACTATT CAAAATCAAA 60 TTTAATCATT TTTATATGGG TATTGAAGCC AACGTTGCGA TGTGGCACAT GTTCCCCTTA 120 TTTCGCGCCA TATAAGCGTA TCCTTTTCTT CCCCAATCAG TTCCCCAGCT GTTTTTAATA 180 ATCCAGTATT CTCCGTATGT TTTATGCTTG CCATAACCGA CAAGTAGTAC TGCGTGATTA 240 AGATCACCAC AGTCACGATT AGAATAAACA CCGGATTTAT AGAATCTAAA A 291 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 216 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: TATGGGTATT GAAGCCAACG TTGCGATGTG GCACATGTTC CCCTTATTTC GCGCCATATA 60- AGCGTATCCT TTTCTTCCCC AATCAGTTCC CCAGCTGTTT TTAATAATCC AGTATTCTCC 120 GTATGTTTTA TGCTTGCCAT AACCGACAAG TAGTACTGCG TGATTAAGAT CACCACAGTC 180 ACGATTAGAA TAAACACCGG ATTTATAGAA TCTAAA 216 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1306 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: GCCGCAAATT ATTGCCCTCA AACATAGATG AAAGTTAGAA TTTGGCCAAT AAATACTATT 60 CAAAATCAAA TTTAATCATT TTTATATGGG TATTGAAGCC AACGTTGCGA TGTGGCACAT 120 GTTCCCCTTA TTTCGCGCCA TATAAGCGTA TCCTTTTCTT CCCCAATCAG TTCCCCAGCT 180 GTTTTTAATA ATCCAGTATT CTCCGTACGT TTTATGCTTG CCATAACCGA CAAGTAGTAC 240 TGCGTGATTA AGATCACCAC AGTCACGATT AGAATAAACA CCGGATTTAT AGAATCTAAA 300 AGGACGCTTT GATCCGTTAA TTCCAACAAC AACGGGTCCA TGCTTAGCCA CAGCATGCAT 360 AAGTCCTAAT TCATCACCCC TTTGTATTGC AGCGTAACCC TTATCAGTGG CGTAACAAAT 420 TTTCTCTTGC CATTTGCATT TTTGTTCAGT CCCAACGTAC GGATATTTCG ATTCCATCGC 480 TAATCCAAAC TTCGTTGCAT AATAGAAAAT TGGATTCATA TAGCCACCAC GACAGCCATA 540 GTTACCCAAC GTCCATGTGC AGTCAACAGC ATTTTGGATG GATAAATCGA CAAGTTTCCC 600 TGTCTTTTTC TTATTATAAG CTTCCAATGC ACCTATTGCA GCGAATCGAT AGCAGCTGCC 660 ACACACTCCT TGATTTTTGA CGGGTGTGAC CATGCCTTTC TTTCTCCAGT CAACCGACAC 720 CGGCAGTTTC TCATTTGGAT CGTACGTATA TTTTTGACCT ACAGTATGAC GAGTCTGCCT 780 TCTTGTTCGA AGATGAGTTT CATTGGGAAA ACGAAGTCCA TTCATCATTT TGAATTCTTC 840 GTCGGTCAAA TCAGCCAAGT GATTCAGACC ATTTGTATAA GAAATTAGGC CTTGTTCATA 900 TTTTCTATTT GTGGCTTCTG TCATTAATTC ATTACTTTCA AATATTGCCA TTCTCAAATT 960 GGACTCATTT GAGTCGTAGT GTTTTCCGAG AGCCATTACG TAATCATTCC ATTCGGTTTC 1020 TAATTTCTCC ATAGCTCGTA GCTCGCCATT GTCTTCCATT TTTTGAAGAA AAGATTGCAG 1080 AACGGTTGAT TTTTGACTTT CTTTTCCATC GCCGTATTTT TTTACTGCTT TTTTGAAATC 1140 AGTCGTAAGC CTCGTCATAT TGCCTCGCTT GTAATCTTGA TCAAATGTTC CTAGAACTTC 1200 TCGTAGCTGT TGCACTTGGG CATTGAGTGT GACAGTAAAA TCGACTAGGA AGGCGAATAC 1260 GATCAGTAAA ACAATGATCC GAAGCATGAG TTTTTTTCTG CTTCTG 1306 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1203 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: TATGGGTATT GAAGCCAACG TTGCGATGTG GCACATGTTC CCCTTATTTC GCGCCATATA 60 AGCGTATCCT TTTCTTCCCC AATCAGTTCC CCAGCTGTTT TTAATAATCC AGTATTCTCC 120 GTACGTTTTA TGCTTGCCAT AACCGACAAG TAGTACTGCG TGATTAAGAT CACCACAGTC 180 ACGATTAGAA TAAACACCGG ATTTATAGAA TCTAAAAGGA CGCTTTGATC CGTTAATTCC 240 AACAACAACG GGTCCATGCT TAGCCACAGC ATGCATAAGT CCTAATTCAT CACCCCTTTG 300 TATTGCAGCG TAACCCTTAT CAGTGGCGTA ACAAATTTTC TCTTGCCATT TGCATTTTTG 360 TTCAGTCCCA ACGTACGGAT ATTTCGATTC CATCGCTAAT CCAAACTTCG TTGCATAATA 420 GAAAATTGGA TTCATATAGC CACCACGACA GCCATAGTTA CCCAACGTCC ATGTGCAGTC 480 AACAGCATTT TGGATGGATA AATCGACAAG TTTCCCTGTC TTTTTCTTAT TATAAGCTTC 540 CAATGCACCT ATTGCAGCGA ATCGATAGCA GCTGCCACAC ACTCCTTGAT TTTTGACGGG 600 TGTGACCATG CCTTTCTTTC TCCAGTCAAC CGACACCGGC AGTTTCTCAT TTGGATCGTA 660 CGTATATTTT TGACCTACAG TATGACGAGT CTGCCTTCTT GTTCGAAGAT GAGTTTCATT 720 GGGAAAACGA AGTCCATTCA TCATTTTGAA TTCTTCGTCG GTCAAATCAG CCAAGTGATT 780 CAGACCATTT GTATAAGAAA TTAGGCCTTG TTCATATTTT CTATTTGTGG CTTCTGTCAT 840 TAATTCATTA CTTTCAAATA TTGCCATTCT CAAATTGGAC TCATTTGAGT CGTAGTGTTT 900 TCCGAGAGCC ATTACGTAAT CATTCCATTC GGTTTCTAAT TTCTCCATAG CTCGTAGCTC 960 GCCATTGTCT TCCATTTTTT GAAGAAAAGA TTGCAGAACG GTTGATTTTT GACTTTCTTT 1020 TCCATCGCCG TATTTTTTTA CTGCTTTTTT GAAATCAGTC GTAAGCCTCG TCATATTGCC 1080 TCGCTTGTAA TCTTGATCAA ATGTTCCTAG AACTTCTCGT AGCTGTTGCA CTTGGGCATT 1140 GAGTGTGACA GTAAAATCGA CTAGGAAGGC GAATACGATC AGTAAAACAA TGATCCGAAG 1200 CAT 1203 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 401 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: Met Leu Arg He He Val Leu Leu He Val Phe Ala Phe Leu Val Asp 1 5 10 15 Phe Thr Val Thr Leu Asn Ala Gin Val Gin Gin Leu Arg Glu Val Leu 20 25 30 Gly Thr Phe Asp Gin Asp Tyr Lys Arg Gly Asn Met Thr Arg Leu Thr 35 40 45 Thr Asp Phe Lys Lys Ala Val Lys Lys Tyr Gly Asp Gly Lys Glu Ser 50 55 60 Gin Lys Ser Thr Val Leu Gin Ser Phe Leu Gin Lys Met Glu Asp Asn 65 70 75 80 Gly Glu Leu Arg Ala Met Glu Lys Leu Glu Thr Glu Trp Asn Asp Tyr 85 90 95 Val Met Ala Leu Gly Lys His Tyr Asp Ser Asn Glu Ser Asn Leu Arg 100 105 110 Met Ala He Phe Glu Ser Asn Glu Leu Met Thr Glu Ala Thr Asn Arg 115 120 125 Lys Tyr Glu Gin Gly Leu He Ser Tyr Thr Asn Gly Leu Asn His Leu 130 135 140 Ala Asp Leu Thr Asp Glu Glu Phe Lys Met Met Asn Gly Leu Arg Phe 145 150 155 160 Pro Asn Glu Thr His Leu Arg Thr Arg Arg Gin Thr Arg His Thr Val 165 170 175 Gly Gin Lys Tyr Thr Tyr Asp Pro Asn Glu Lys Leu Pro Val Ser Val 180 185 190 Asp Trp Arg Lys Lys Gly Met Val Thr Pro Val Lys Asn Gin Gly Val 195 200 205 Cys Gly Ser Cys Tyr Arg Phe Ala Ala He Gly Ala Leu Glu Ala Tyr 210 215 220 Asn Lys Lys Lys Thr Gly Lys Leu Val Asp Leu Ser He Gin Asn Ala 225 230 235 240 Val Asp Cys Thr Trp Thr Leu Gly Asn Tyr Gly Cys Arg Gly Gly Tyr 245 250 255 Met Asn Pro He Phe Tyr Tyr Ala Thr Lys Phe Gly Leu Ala Met Glu 260 265 270 Ser Lys Tyr Pro Tyr Val Gly Thr Glu Gin Lys Cys Lys Trp Gin Glu 275 280 285 Lys He Cys Tyr Ala Thr Asp Lys Gly Tyr Ala Ala He Gin Arg Gly 290 295 300 Asp Glu Leu Gly Leu Met His Ala Val Ala Lys His Gly Pro Val Val 305 310 315 320 Val Gly He Asn Gly Ser Lys Arg Pro Phe Arg Phe Tyr Lys Ser Gly 325 330 335 Val Tyr Ser Asn Arg Asp Cys Gly Asp Leu Asn His Ala Val Leu Leu 340 345 350 Val Gly Tyr Gly Lys His Lys Thr Tyr Gly Glu Tyr Trp He He Lys 355 360 365 Asn Ser Trp Gly Thr Asp Trp Gly Arg Lys Gly Tyr Ala Tyr Met Ala 370 375 380 Arg Asn Lys Gly Asn Met Cys His He Ala Thr Leu Ala Ser He Pro 385 390 395 400 He While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.

Claims: What is claimed is: 1. An isolated filariid nematode larval nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene selected from the group consisting of a Dirofilaria immitis L3 cysteine protease gene and an Onchocerca volvulus L3 cysteine protease gene. 2. An isolated protein comprising a filariid nematode larval cysteine protease protein. 3. The protein of Claim 2, wherein said protein is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to a gene selected from the group consisting of a Dirofilaria immitiε L3 cysteine protease gene and an Onchocerca volvuluε L3 cysteine protease gene. 4. The invention of Claim 1 or 3, wherein said D. immitiε L3 cysteine protease gene comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:l, and wherein said O . volvuluε L3 cysteine protease gene comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:5 and SEQ ID NO:14. 5. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule comprises a nucleic acid sequence that encodes a filariid nematode larval cysteine protease protein. 6. The invention of Claim 1 or 2, wherein said filariid nematode is selected from the group consisting of Dirofilaria , Onchocerca , Acanthocheilonema , Brugia , Dipetalonema, Loa , Parafilaria , Setaria , Stephanofilaria and Wuchereria filariid nematodes. 7. The invention of Claim 1 or 2, wherein said filariid nematode is selected from the group consisting of Dirofilaria immitiε and Onchocerca volvuluε . 8. The invention of Claim 1 or 3, wherein said nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of nDiCP 1298 nDiCP 1194 nDiCP 1098 nDiCP 942 , nDiCP 945 , nDiCP 850 , nDiCP 450 , nDiCP 1071 , nθvCP 291 , nθvCP 216 , nθvCP 1306 , nθvCP 1272 and nθvCP 1203 9. The invention of Claim 1 or 3, wherein said nucleic acid molecule is selected from the group consisting of a nucleic acid molecule comprising nucleic acid sequence SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30, or an allelic variant of any of said nucleic acid molecules. 10. The invention of Claim 1 or 3, wherein said nucleic acid molecule encodes a protein selected from the group consisting of a protein comprising an amino acid sequence that is at least about 70 percent identical to amino acid sequence SEQ ID NO:6, a protein that is at least about 40 percent identity to amino acid sequence SEQ ID NO:4 and a protein that is at least about 49 percent identical to amino acid sequence SEQ ID NO:31. 11. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule comprises an oligonucleotide. 12. The invention of Claims 2 or 5, wherein said protein or a mimetope thereof, when administered to an animal is capable of eliciting an immune response against a parasitic helminth cysteine protease protein. 13. A recombinant molecule comprising a nucleic acid molecule as set forth in Claim 1 operatively linked to a transcription control sequence. 14. A recombinant virus comprising a nucleic acid molecule as set forth in Claim 1. 15. A recombinant cell comprising a nucleic acid molecule as set forth in Claim 1, said cell being capable of expressing said nucleic acid molecule. 16. The invention of Claims 2 or 5, wherein said protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:15 and SEQ ID NO:31, or wherein said protein is encoded by an allelic variant of a nucleic acid molecule encoding a protein comprising any of said amino acid sequences. 17. The protein of Claim 2 or 5, wherein said protein is produced by a process comprising culturing a recombinant cell transformed with a nucleic acid molecule encoding said protein to produce said protein. 18. An isolated antibody that selectively binds to a protein as set forth in Claim 2. 19. A therapeutic composition capable of protecting an animal from disease caused by a parasitic helminth, said therapeutic composition comprising a protective compound selected from the group consisting of an isolated filariid nematode larval cysteine protease protein or a mimetope thereof, an isolated filariid nematode larval nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene selected from the group consisting of a D. immitiε L3 cysteine protease gene and an O. volvulus L3 cysteine protease gene, an isolated antibody that selectively binds to a filariid nematode L3 larval cysteine protease protein, an inhibitor of cysteine protease activity identified by its ability to inhibit filariid nematode L3 larval cysteine protease activity, and a mixture thereof. 20. A method to protect an animal from parasitic helminth disease, said method comprising administering to said animal a therapeutic composition comprising a protective compound selected from the group consisting of an isolated filariid nematode larval cysteine protease protein or a mimetope thereof, an isolated filariid nematode larval nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene selected from the group consisting of a 17. immitis L3 cysteine protease gene and an O. volvulus L3 cysteine protease gene, an isolated antibody that selectively binds to a filariid nematode L3 larval cysteine protease protein, an inhibitor of cysteine protease activity identified by its ability to inhibit filariid nematode L3 larval cysteine protease activity, and a mixture thereof. 21. The invention of Claims 19 or 20, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant, a carrier, and a mixture thereof. 22. The invention of Claims 19 or 20, wherein said protective compound is selected from the group consisting of a naked nucleic acid vaccine, a recombinant virus vaccine and a recombinant cell vaccine. 23. The invention of Claims 19 or 20, wherein said parasitic helminth comprises a tissue-migrating helminth. 24. A method to produce a filariid nematode larval cysteine protease protein, said method comprising culturing in an effective medium a cell capable of expressing said protein, said protein being encoded by a filariid nematode nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene selected from the group consisting of a Dirofilaria immitiε L3 larval cysteine protease gene and an Onchocerca volvulus L3 larval cysteine protease gene. 25. A method to identify a compound capable of inhibiting cysteine protease activity of a parasitic helminth, said method comprising: (a) contacting an isolated filariid nematode larval cysteine protease protein with a putative inhibitory compound under conditions in which, in the absence of said compound, said protein has cysteine protease activity; and (b) determining if said putative inhibitory compound inhibits said cysteine protease activity. 26. A test kit to identify a compound capable of inhibiting cysteine protease activity of a parasitic helminth, said test kit comprising an isolated filariid nematode larval cysteine protease protein having cysteine protease activity and a means for determining the extent of inhibition of said activity in the presence of a putative inhibitory compound.

Inventors: FRANK GLENN R, GRIEVE ROBERT B, TRIPP CYNTHIA ANN, WISNEWSKI NANCY, FRANK, GLENN, R., GRIEVE, ROBERT, B., TRIPP, CYNTHIA, ANN, WISNEWSKI, NANCY
Applicants: FRANK GLENN R, GRIEVE ROBERT B, HESKA CORP, TRIPP CYNTHIA ANN, UNIV COLORADO RES, WISNEWSKI NANCY, COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, FRANK, GLENN, R., GRIEVE, ROBERT, B., HESKA CORPORATION, TRIPP, CYNTHIA, ANN, WISNEWSKI, NANCY
Application year: 1996
Main classification: C12N9
IPC codes: A61K35, A61K38, A61K39, A61K48, A61P33, C07K14, C07K16, C12N7, C12N9, C12N15, C12Q1, G01N33